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ABSTRACT
Insulin resistance is a condition that underlies type 2 diabetes and various cardiovascular
diseases. It is highly associated with obesity, making it a pressing medical problem in
face of the obesity epidemic. The obesity association also makes adipose tissue the target
of interest for ongoing research. Previous work on adipose insulin resistance has largely
been focused on deciphering the signaling defects and abnormal adipokine secretion
profiles. There is increasing awareness that transcriptional control is a source of
dysregulation as well as an avenue of therapeutic intervention for insulin resistance.
However, knowledge of transcriptional regulation and dysregulation of adipose insulin
resistance remains fragmentary.
Here, we present a genome-wide perspective on transcriptional regulation of
adipocyte biology and adipose insulin resistance. We made use of the latest high-
throughput sequencing technology to interrogate different aspects of transcriptional
regulation, namely, histone modifications, protein-DNA interactions, and chromatin
accessibility in adipocytes. In combination with the transcriptional outcomes measured
by microarray and RNA-sequencing, we (1) characterized a largely unknown histone
modification, H3K56 acetylation, in human adipocytes, and (2) set up four diverse in
vitro insulin resistance models in mouse adipocytes and analyzed them in parallel with
mouse adipose tissues from diet-induced obese mice. In both cases, through
computational analysis of the experimentally identified cis-regulatory regions, we
identified existing and novel trans-regulators responsible for adipose transcriptional
regulation. Furthermore, by comprehensive pathway analysis of the in vitro models and
mouse models, we identified aspects of in vivo adipose insulin resistance that are
captured by the different in vitro models. Taken together, our studies present a systems
view on adipose transcriptional regulation, which provides a wealth of novel resources
for gaining insights into adipose biology and insulin resistance.
Thesis Supervisor Ernest Fraenkel
Title: Eugene Bell Associate Professor of Biological Engineering
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1. Introduction
1.1 Overview
One of the most fundamental problems of modem biology is how the different cell types
in a multicellular organism, while all (except gametes in the case of mammals)
possessing the same set of genomic instructions encoded as DNA, are able to establish
diverse cellular identities to perform numerous highly specialized functions. Furthermore,
cellular states are highly dynamic in response to intracellular signaling cascades and
diverse environmental cues. Transcriptional regulation has a primary role in both
establishing and maintaining diverse cell types and cellular states. It governs basic
developmental processes such as the self-renewal versus differentiation decisions of
embryonic stem cells and lineage specification of hematopoietic stem cells. For
differentiated cell types such as adipocytes, proper transcriptional regulation is crucial for
maintaining normal cellular functions. Conversely, transcriptional dysregulation could
lead to diseases, one example of which is insulin resistance, the topic of this thesis. Since
transcriptional regulation is highly plastic, manipulating this process is an effective way
to ameliorate diseases. It is with such premises that we undertake the current study of
understanding transcriptional regulation of insulin resistance.
Transcription is under tight regulation at multiple levels: The nucleosome
structure of DNA intrinsically imposes a steric hindrance for transcription to occur. By
modifying the accessibility of cis-regulatory elements, transcription can be enhanced or
hindered. Chromatin structure is also affected by epigenetic modifications such as DNA
methylation and histone modifications. Finally, trans-acting factors such as transcription
factors and coregulators, in cooperation with the basic transcription machinery, serve as
the actual executors of transcription by binding to various cis-regulatory elements.
The first part of this chapter discusses the problem of insulin resistance, with a
focus on white adipose tissue and its transcriptional regulation/dysregulation. The second
part talks about the different methodologies for studying transcriptional regulation and
the current knowledge from applying those methods on adipocyte function and insulin
resistance. The background information provided is not meant to be exhaustive; readers
are referred to the many excellent reviews on these topics cited throughout the chapter.
1.2 The problem of insulin resistance
1.2.1 Definition and human perspective
Insulin resistance, on the cellular level, refers to the condition in which there is reduced
ability of a cell to respond to the physiological level of insulin. Insulin resistance
increases the risk of developing type 2 diabetes, cardiovascular diseases, essential
hypertension, polycystic ovary syndrome, nonalcoholic fatty liver disease, sleep apnea
and certain forms of cancers (Reaven 2005).
According to the European Group for the Study of Insulin Resistance (EGIR),
insulin resistance is defined as hyperinsulinemia associated with two or more of the other
components: hyperglycemia, hypertension, dyslipidemia, and central obesity. This
definition is very similar to that of syndrome X, a termed coined by endocrinologist
Gerald M Reaven in 1988. He proposed that insulin resistance is the underlying factor of
the above metabolic abnormalities which he subsumed under the name syndrome X
(Reaven 1988).
As the role of insulin resistance in human metabolic diseases became more
apparent, the cardiology community formally acknowledged that insulin resistance
predisposes the development of cardiovascular diseases. The term metabolic syndrome
was introduced to refer to the "constellation of lipid and nonlipid risk factors of metabolic
origin" (Expert Panel on Detection and Adults 2001). The present consensus is that
metabolic syndrome is meant to serve as a clinical diagnosis criterion, and insulin
resistance is the name given to the cardinal physiological abnormality associated with
metabolic syndrome (Reaven 2004).
Insulin resistance is best assessed by euglycemic hyperinsulinemic clamping,
which consists of a constant infusion of insulin with a parallel infusion of glucose to
ensure euglycemia. The amount of glucose needed to maintain euglycemia under the
controlled hyperinsulinemia is used to evaluate insulin sensitivity. Alternatively, for
large epidemiological studies and for practical reasons, EGIR proposes the use of
hyperinsulinemia, defined as having fasting insulin levels in the upper 25%, as a
surrogate marker of insulin resistance. This definition highlights the prevalence (as much
as 25% of the population) of insulin resistance.
It is alarming that the rate of insulin resistance has been escalating due to modem
sedentary lifestyle and the consumption of a high-fat high calorie diet. This underscores
a salient feature of insulin resistance: obesity predisposes people to insulin resistance
(Kim and Reaven 2010). Given the metabolic abnormalities that insulin resistance is
associated with and the economic and social burden that these diseases impose on society
and individuals, there is an urgent need to better understand the mechanisms of insulin
resistance.
1.2.2 The actions of insulin and insulin signaling pathway
Before proceeding to discuss how the insulin response is impaired during insulin
resistance, we need to understand what constitutes a normal insulin response. Insulin is a
hormone secreted by the [ cells of the pancreatic islets of Langerhans in response to
rising blood glucose level. While its short-term effects are mainly on maintaining whole-
body glucose and lipid homeostasis, it has long-term effects on growth and development.
In this thesis, we focus on the short-term metabolic role of insulin.
On the molecular level, insulin exerts its action on the insulin receptor, which is a
tyrosine kinase consists of two alpha subunits and two beta subunits. Binding of insulin
to the extracellular alpha subunits induces a series of tyrosine autophosphorylation on the
tyrosine kinase domains of the intracellular beta subunits. Once the insulin receptor is
activated by autophosphorylation, it goes on to phosphorylate a number of important
substrates. These include various isoforms of insulin receptor substrate (IRS 1/2/3/4), the
Shc adaptor protein, SIRP family members, Gab-1, Cbl, and APS. Each of these
substrates recruits a distinct sets of Src-homology 2 (SH2) domain-containing proteins,
which interact with sequences surrounding the phosphotryosine residue of the insulin
receptor.
Two main branches propagate signals downstream of the insulin receptor: the
insulin receptor substrate/phosphatidylinositol 3-kinase pathway (IRS/PI3-K) and the
Ras/mitogen-activated protein kinase (MAPK) pathway. We will focus on the IRS/PI3-K
arm here as it mediates most of the short-term metabolic effects of insulin. IRS 1 is the
insulin receptor substrate that is most studied. Tyrosine phosphorylated IRS1 recruits,
among others, the p85 regulatory subunit of the type 1A PI 3-K. This activates the
catalytic subunit (p110) of PI 3-K, which phosphorylates the phosphatidylinositol on the
D3 position of the inositol ring, leading to the generation of PI 3-phophate (PIP3). PIP3
acts as an intracellular messenger; it leads to the activation of PDKs, Akt, (also known as
protein kinase B, PKB), and the atypical protein kinase C isoforms ( and X (PKC fr),
which in turn activate other downstream signaling molecules to mediate the diverse
actions of insulin (Pessin and Saltiel 2000).
Insulin exerts its actions mainly but not exclusively on the three main metabolic
organs: liver, muscle and fat (white adipose tissue). Other insulin targeting tissues
include the heart, the hypothalamus, the kidney and the pancreas. The effects of insulin
are largely anabolic and tissue specific: in the liver, insulin suppresses de novo glucose
synthesis (gluconeogenesis) and the breaking down of glycogen (glycogenolysis). In
muscle and white adipose tissue, it leads to an increase in glucose uptake, which is
dependent on the translocation of the glucose transporter Glut4 onto the plasma
membrane. Although skeletal muscle is responsible for - 90% of glucose disposal,
adipocyte-specific Glut4 knock-out mice are insulin resistant (Abel, Peroni et al. 2001),
indicating that adipose glucose uptake has a systemic effect on insulin sensitivity.
Besides regulating glucose uptake, insulin has a profound effect on lipid metabolism
(Saltiel and Kahn 2001): it increases lipid synthesis in the liver and fat, and it suppresses
lipolysis (breaking down of triglycerides and the release of free fatty acids) in fat and
muscle. Insulin stimulates amino acid uptake and promotes protein synthesis on virtually
all tissues. It also has mitogenic effects by stimulating DNA synthesis and preventing
apoptosis.
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Figure 1-1 Signal transduction in the insulin signaling pathway
The insulin receptor is a tyrosine kinase that undergoes autophosphorylation and
catalyses the phosphorylation of many intracellular proteins such as members of the IRS
family, Shc and Cbl. Upon tyrosine phosphorylation, these proteins interact with
signaling molecules through their SH2 domains, resulting in a diverse series of signaling
pathways, including activation of P13-K and downstream PIP3-dependent protein kinases,
ras and the MAP kinase cascade, and Cbl/CAP and the activation of TC10. These
pathways act in a concerted fashion to coordinate the regulation of vesicle trafficking,
protein synthesis, enzyme activation and inactivation, and gene expression, which results
in the regulation of glucose, lipid and protein metabolism. Adapted by permission from
Macmillan Magazines Ltd: Nature (Saltiel and Kahn, 2001), copyright 2001.
receptors
, '6 ' I
1.2.3 Insulin resistance in white adipose tissue
In this thesis, we focus on cellular insulin resistance in white adipose tissue and white
adipocytes (termed adipocytes hereafter). The unique functions of adipocyte make this
cell type a critical component of energy homeostasis and systemic metabolic control
(Rosen and Spiegelman 2006). As mentioned above, adipocyte is the main energy
storage organ in the body by converting free fatty acids into triglycerides. In the adipose
insulin resistant state, there is an increase in circulating free fatty acids due to the reduced
ability to repress lipolysis as a consequence of insulin resistance. This leads to ectopic
accumulation of triglycerides and fatty-acid derived metabolites (e.g., diacylglycerol,
fatty acyl-CoA and ceramides) in muscle and the liver, which may severely affect their
normal functions. This phenomenon is known as lipotoxicity (Schaffer 2003). Besides
acting as an energy storage organ, adipocyte is also an endocrine organ (Tilg and
Moschen 2006). It does so by secreting soluble mediators called adipokines, some of
which are exclusively produced by adipocytes, such as adiponectin and leptin, and others
are produced by adipocytes and the surrounding cells, such as TNFa, IL-6, IL-1, CC-
chemokine ligand 2 (MCP2) and plasminogen activator inhibitor (PAI). These molecules
exert systemic effects on whole-body insulin sensitivity by regulating signaling both in
adipocyte and other tissues. For example, adiponectin acts on the liver to suppress
inflammation, and leptin inhibits appetite by acting on the hypothalamus. A notable
example of the systemic role of adipocyte in mediating insulin sensitivity is illustrated by
the adipocyte-specific c-Jun NH(2)-terminal kinase (JNK) knock-out mice: these mice
are protected from hepatic insulin resistance as a result of decreased secretion of IL-6
from adipose tissue and the prevention of SOCS3 activation in the liver (Sabio, Das et al.
2008).
Other aspects of fat cell biology are important to whole-body insulin sensitivity.
The scope of this thesis does not allow further discussion of these aspects, the overview
below aims to highlight the complexity of the system. Firstly, there are two types of
adipose tissue: brown adipose tissue and white adipose tissue. Brown adipose tissue is
mainly involved in non-shivering thermogenesis; it is a fat burning organ. Conversely,
white adipose tissue is a fat storing organ; it stores excess energy in the form of
triglycerides. This thesis is on insulin resistance in white adipose tissue and white
adipocytes. Secondly, white adipose tissue refers to a collection of mature adipocytes,
preadipocytes, mesenchymal stem cells, fibroblasts, endothelial cells and immune cells,
with adipocytes being the major component of adipose tissue. However, during diseased
state, the infiltration of immune cells (especially macrophages) becomes substantial; they
exert adverse effects on the normal functions of adipocytes. Thirdly, not all white fats
are created equal: white adipocytes in different anatomical locations have different
impact on insulin sensitivity. Visceral obesity is perceived to be more detrimental than
subcutaneous obesity as the former is related to the accumulation of fat in the abdominal
cavity, which is drained by the portal vein and therefore has direct access to the liver
(Bergman, Kim et al. 2006). Fourthly, bigger fat cells are more insulin resistant than
smaller fat cells (Salans and Dougherty 1971). Most intriguingly, obesity does not
always lead to insulin resistance, or conversely, people of healthy-weight are not immune
to insulin resistance.
It could be argued that a systemic study of insulin resistance requires studies on
animal models, in which tissue-tissue crosstalk and physiological compensatory changes
in different tissues take place. However, experimentation with isolated cellular models
has its own advantages: it allows extracellular environment to be carefully designed and
controlled. We agree that an animal model is a superior system in studying whole-body
physiology, but a cell line model could serve as the first step to tease out the complexities
on the cellular level.
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Figure 1-2 Adipocytes exert systemic control of whole-body insulin sensitivity
Adipocytes affect whole-body insulin sensitivity via two main ways. Firstly, it stores
excess fatty acids in the form of triglycerides and mediates the breakdown of
triglycerides to free fatty acid (lipolysis) in time of need (e.g., starvation). In the insulin
resistant state, lipolysis is elevated. This leads to an increase in the levels of circulating
free fatty acids and fatty acid derivatives, eventually result in ectopic accumulation of
lipid in non-adipose organs, causing lipotoxicity. Secondly, adipocytes secrete a wide
range of signaling molecules, widely termed adipokines, which have systemic effects on
insulin sensitivity. For example, in the insulin resistant state, adiponectin secretion is
reduced while TNFa and IL-6 levels are increased. Maintaining the delicate balance of
these processes is crucial in maintaining whole-body insulin sensitivity.
1.2.4 Transcriptional versus signaling changes in insulin resistance
Given that phosphorylation cascades constitute the basic mechanism of insulin action, it
is not surprising that insulin resistance is associated with defects in many important nodes
along the insulin signaling pathway (Taniguchi, Emanuelli et al. 2006). One such
example is the serine phosphorylation of IRS 1, which has been shown to increase
degradation of IRS 1 and interfere with its interaction with the upstream insulin receptor
(Zick 2004).
IRS1 is serine-phosphorylated by multiple kinases, two such examples are JNK
(Rui, Aguirre et al. 2001) and inhibitor kappaB kinase (IKK) (Gao, Hwang et al. 2002).
JNK is a member of the MAP kinase family. It is activated primarily by cytokines and
environmental stresses (Weston and Davis 2007). IKK is part of the NF-4B signal
transduction cascade that mediates inflammation. Both kinases lead to activation of
transcription factors: JNK, as its name suggests, phosphorylates and activates the
transcription factor c-Jun, a component of the AP-1 family; IKK phosphorylates inhibitor
of kappa B (IcB), thus removing the inhibition on the transcription factor NF-cB. Both
AP-1 and NF-cB have long been implicated in insulin resistance. The crosstalk among
kinases, transcription factors and signaling molecules highlights that both transcriptional
and phosphorylation signaling regulations are inextricably intertwined. Consider the
scenario where transcriptional control is dysregulated and gene expression is altered. The
gene expression changes eventually manifest themselves as changes in protein and post-
translational modification levels of signaling molecules. Since insulin resistance
develops over the time scale of months or even years, it is almost certain that both
signaling and transcriptional derangements underlie this chronic condition.
The importance of transcriptional regulation in insulin resistance is well
illustrated by the anti-diabetic drug, thiazolidinedione (TZD). TZD enhances insulin
sensitivity by improving glucose and lipid metabolism, altering adipokine secretion, and
reducing adipose tissue inflammatory responses. It does so mainly by activating the
transcription factor peroxisome proliferator-activator receptor gamma (PPARy) (Figure
1-3). A set of genes that explain the actions of TZD in insulin sensitization in human
diabetics patients has recently been identified (Sears, Hsiao et al. 2009). This confirms
that modifying the transcriptional outcome is an effective way to ameliorate insulin
resistance. However, simply activating PPARy activity may have unexpected negative
effects. It was shown that heterozygous PPARy-deficient mice are protected from the
development of high-fat diet-induced insulin resistance. However, the protective effects
of PPARy heterozygosity are abrogated by PPARy agonist treatment (Kubota, Terauchi et
al. 1999). This confounding result highlights the complexity of transcriptional regulation
in mediating insulin sensitivity.
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Figure 1-3 The role of transcription in insulin resistance
Top: Improper activation of transcription factors can lead to insulin resistance. For
example, activation of NF-icB is obligatory in causing insulin resistance in 3T3-L1
adipocytes by TNFa. NF-icB exerts its action by binding to the cis-regulatory elements
on DNA, leading to an increase in the expression of many inflammatory genes and
preadipocyte genes. Bottom: Transcriptional regulation can also be an effective
therapeutic strategy to ameliorate insulin resistance. A widely-used antidiabetic drug,
TZD, acts by this mechanism. Metformin acts on a coactivator called CBP while TZD
acts by activating the transcription factor PPARy, leading to a gene expression program
that restore insulin sensitivity.
1.3 Unraveling transcriptional regulation of
insulin resistance
The purpose of this section is to discuss the various sequencing-based genome-wide
approaches for transcriptional regulation analysis that this thesis employs (Figure 1-4).
Specific examples are provided to illustrate how the application of these approaches has
enhanced our understanding of adipose biology. Efforts are made to provide examples
relevant to adipose insulin resistance; however, in the field of adipose biology, most
studies employing these approaches have largely been on adipogenesis, thus most
examples given here are related to transcriptional regulation of adipogenesis.
Figure 1-4 Overview of the methods employed in this thesis to study transcriptional
regulation and transcriptional outcome
On the transcriptional regulation level, ChIP-Seq was used to investigate genome-wide
histone modification and DNA-protein interaction in adipocytes. DHS-Seq was used to
unravel chromatin accessibility by identifying the DNase I hypersensitivity regions.
These techniques allow the identifications of cis-regulatory elements, as well as trans-
regulatory factors through DNA sequence motif analysis. Transcriptional outcome was
measured by RNA-Seq or microarray. Data from these approaches were analyzed in
combination to increase our understanding of adipose biology and adipose insulin
resistance. Adapted from http://genome.ucsc.edu/ENCODE/
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1.3.1 Histone modifications
Histone proteins are subjected to a number of covalent modifications: methylation,
acetylation, phosphorylation, ubiquitylation and ADP-ribosylation. Histone
modifications have been linked to transcription initiation (H3K4me3), repression
(H3K27me3, H3K9me3), open chromatin regions (H3K4me2/mel and H3K27ac) and
transcription elongation (H3K36me3), etc. A histone code was proposed to explain how
multiple histone modifications act sequentially or in combination to influence
downstream transcriptional events. (Strahl and Allis 2000). Histone modifications,
together with DNA methylation, are collectively termed epigenetic regulation, which is
loci-specific nongenetic chromatin regulation that influences gene transcription but is
nonetheless inherited and self-propagated through cell division (Campos and Reinberg
2009).
The method of choice in mapping genome-wide histone modifications is
chromatin immunoprecipitation (ChIP) experiment followed by microarray (ChIP-chip)
or high-throughput sequencing (ChIP-Seq) (Schones and Zhao 2008). ChIP involves first
capturing DNA-protein interactions (as well as protein-protein interactions) using a
crosslinking agent (usually formaldehyde) in intact cells. Following crosslinking, cells
are lysed and DNA is fragmented into < 1000 bp by sonication. An antibody specific to
the histone modification of interest (or protein of interest in the case of transcription
factor ChIP) is used to immunoprecipitate the particular protein-DNA complexes. The
immunoprecipitated DNA-protein complexes are then reverse-crosslinked. The DNA is
purified, labeled and hybridized to a microarray or subject to high-throughput sequencing.
Sequenced reads are mapped to reference genomes, and genomic regions with
significantly more mapped reads than background are identified using various peak
calling algorithms (Pepke, Wold et al. 2009). These regions represent sites with
particular histone modification(s).
Comprehensive histone modification profiling has been carried out to delineate
the chromatin state changes during various developmental processes (Mikkelsen, Ku et al.
2007; Lien, Guo et al. 2011; Wong, Hattangadi et al. 2011). Mikkelsen et al recently
profiled 6 histone modifications (H3K4me3/me2/mel, H3K27me/ac, and H3K36me3) at
4 different time-points during adipogenesis (Mikkelsen, Xu et al. 2010). Using the
H3K27ac mark as a signature for distal enhancers, thousands of regions with increased
(or decreased) H3K27ac levels during adipogenesis were discovered. These regions are
found to be more likely to associate with induced (or repressed) genes during
adipogenesis. Focusing on the adipocyte-specific H3K27ac sites on genomic region of
the long-chain fatty acid transporter CD36, they found that 5 out of 6 such sites show
enhancer activity. This example illustrates that histone modification analysis is an
effective way to identify functional cis-regulatory elements.
Histone modification profiling is often performed in combination with
transcription factor and co-regulator binding sites analysis. In the above study, the
chromatin state maps prior and after adipogenesis were used to identify novel trans-
regulators involved in the process. Based on DNA sequence motif analysis of regions
with preadipocyte-specific H3K27ac mark, promyelocytic leukemia zinc finger protein
(PLZF) and serum response factor (SRF) were proposed to have repressor functions on
adipogenesis. The authors show by both loss- and gain-of-function experiments that it is
indeed the case. This highlights the utilities of integrating epigenomic profiling with
DNA sequence motif analysis for identification of trans-regulators.
1.3.2 Transcription factor and coregulator binding
Although histone modification profiling with motif analysis can be used to predict
transcription factor binding sites, the actual binding evidence comes from genome-wide
transcription factor ChIP experiments. The same ChIP-chip or ChIP-Seq techniques for
profiling histone modifications are used for transcription factor and coregulator binding
sites analysis (Figure 1-5). However, ChIP on a transcription factor or coregulator often
requires more starting materials (in the magnitude of tens of millions cells) compared to a
histone modification ChIP. New developments in technique have begun to provide
means to lower the cell number requirement (Adli, Zhu et al. 2010; Adli and Bernstein
2011; Shankaranarayanan, Mendoza-Parra et al. 2011). In our experience, histone
modification ChIP-Seq seems to work the most consistently and require the least number
of cells (1-5 million or even less). Transcription factor ChIP often requires more than 30
million cells per experiment, and coregulator ChIP is even harder to perform, probably
due to the fact that coregulators do not interact with DNA directly; they are instead
connect to DNA through protein-protein interaction. We found that the amount of cells
required is also critically dependent on the strength of the "pulling-down" power of the
antibody and the abundance of the protein under study. The ENCODE Consortium has
provided a set of guidelines in validating antibody suitable for histone ChIP experiments
(Kapren and Strome 2008), most of these guidelines are applicable for transcription
factor ChIP as well. One way to overcome the lack of suitable ChIP-grade antibody is to
generate a specific tagged-version (e.g. FLAG-tag, HA-tag) of the protein of interest;
however, the tagged-protein may not behave like the endogenous protein. These issues
highlight the experimental challenges of performing transcription factor ChIP
experiments.
Simultaneously profiling genome-wide binding sites for multiple transcription
factors could shed new insights into transcriptional regulation. PPARy and C/EBPi, the
two major adipocyte transcription factors, were found to occupy adjacent genomic
locations of many upregulated genes during adipogenesis, suggesting that both
transcription factors coordinate the gene expression repertoire that defines the adipocyte
phenotype (Lefterova, Zhang et al. 2008). ChIP-chip and ChIP-Seq analyses have also
been used to delineate the epigenomic transition during adipogenesis (Steger, Grant et al.
2010; Siersbaek, Nielsen et al. 2011). In response to the adipocyte differentiation
cocktail, glucocorticoid receptor (GR) and C/EBPp are activated. The study by Steger et
al provides experimental evidence that GR, C/EBPP, p300 and mediator subunit 1 (Medl)
together bind many genes involved in cell proliferation, development and differentiation.
Siersbaek et al further show that RXR and Stat5a are also involved in early adipocyte
differentiation by forming transcription factors "hotspots". In addition, C/EBPp co-
occupies a large number of these hotspots even prior to the induction of differentiation,
suggesting that C/EBP$ may act as a pioneering factor for adipogenic transcription
factors and chromatin remodeling. These studies unravel the extensive and highly
dynamic transcription factor network during adipogenesis, which is previously
unrecognized and impossible to decipher without these genome-wide high-throughput
experiments.
Compared to that of adipogenesis, genome-wide studies of the transcription factor
network in insulin resistance are lacking. Inproper activation of transcription factors
such as NF-B and AP-1 have long been implicated in insulin resistance; however, their
genome-wide binding sites and target genes have not been mapped. Besides NF-B and
AP- 1, recent studies suggest that other transcription factors such as p53 (Minamino,
Orimo et al. 2009), CREB (Qi, Saberi et al. 2009) and Smad3 (Yadav, Quijano et al. 2011)
are also related to adipose insulin resistance. The previously unrecognized involvements
of these transcription factors in insulin resistance were often discovered from observing
the phenotypes of knock-out mice (e.g., adipocyte-specific p53 and CREB knock-out
mice are both protected from high-fat diet-induced insulin resistance). These knock-out
mice were in turn generated based on existing knowledge and previous studies. In order
to discover novel transcription factors involved in insulin resistance, a truly unbiased
approach is needed.
1.3.3 Chromatin accessibility
DNA in eukaryotes is organized into chromatin, the basic unit of which is nucleosome,
which consists of - 150bp of DNA tightly wrapped around a histone core. This structure
renders the majority of DNA inaccessible to trans-acting factor binding. Conversely,
active cis-regulatory regions have altered local chromatin architecture due to the
disruption of the regular nucleosome structure, allowing protein-DNA interactions to take
place. As a result, these regions are more susceptible to digestion by the endonuclease
DNase I (Wu, Bingham et al. 1979); they are termed DNase hypersensitive (DHS)
regions (Evanko 2006; Hager 2009). Traditionally, DNase hypersensitivity analysis has
been performed by treating intact nuclei with DNase I and measuring the extent of cutting
by Southern blot hybridization, which detects the DNase I cleavage events occurring in a
specific genomic location with respect to a selected probe. However, such approach is
laborious and low throughput. The advent of microarray and high-throughput sequencing
technology makes it possible to detect the genome-wide DNase I hypersensitive regions
in a single DHS-array or DHS-Seq experiment (Sabo, Kuehn et al. 2006; Boyle, Song et
al. 2011). There are other experimental methods that can map accessible chromatin
regions, such as Sono-Seq (Auerbach, Euskirchen et al. 2009)and FAIRE-Seq (Giresi,
Kim et al. 2007). Since all these techniques are relatively new, very few comparisons
have been made among them. In a recent study that uses both FAIRE-Seq and DHS-Seq
to identify regulatory elements in 7 different cell lines, the two techniques identify
overlapping and unique sets of open chromatin sites, suggesting that they are
complementary approaches (Song, Zhang et al. 2011). In this thesis, we employ the DHS-
Seq method to identify novel regulator(s) of insulin resistance.
There are two main DHS-Seq approaches, their difference lies in the way the
DNase-digested fragments are isolated (Giresi and Lieb 2006). The first approach
involves attaching biotinylated tags to the ends of the DNase I-cleaved DNA. Once the
cleaved sites have been tagged, the DNA are sonicated into smaller fragments of 200-
500bp and subsequently captured by streptavidin pull-down (Crawford, Holt et al. 2004).
The second method involves isolating DNA fragments as a result of two nearby cleavage
events; it is believed that in DNase hypersensitive regions, multiple cleavage events in
close proximity are more likely to occur. Those DNA fragments produced by two nearby
cleavage events (<500bp) are called "two-hit" fragments. These "two-hit" fragments are
purified by a sucrose density gradient (Sabo, Kuehn et al. 2006; Hesselberth, Chen et al.
2009) (Figure 1-5). In our study, we adopt the second method.
DNase hypersensitivity analysis has been applied to identify novel regulators of
adipogenesis (Eguchi, Yan et al. 2008). Using a qPCR-based DHS assay combined with
motif analysis of the DHS sites, Eguchi et al discovered that interferon regulatory factors
(IRFs) are endogenous regulators of adipogenesis and adipocyte gene expression. Using
the same sets of data, COUP-TFII has been suggested to be a negative regulator of
adipogenesis (Xu, Yu et al. 2008). So far, no studies have been done to investigate the
DNase hypersensitivity changes upon insulin resistance.
While histone modification profiling combined with motif analysis have
successfully been used to identify novel trans-regulators, prior knowledge on which
particular histone modification to investigate is required; this introduces bias into the
study. DNase hypersensitivity analysis is unbiased because there is no need to pre-select
targets for immunoprecipitation. The ability to bypass the immunoprecipitation step also
makes DNase hypersensitivity analysis free from the typical problems that affect ChIP,
such as the unavailability of suitable antibodies, the lack of specificity of "dirty"
antibodies and the inefficiency of the immunoprecipitation procedure. A comparison of
ChIP and DNase hypersensitivity analysis is shown in Figure 1-5.
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Figure 1-5 Comparison between ChIP-Seq and DHS-Seq
Both techniques are used to interrogate transcriptional regulation. Right: ChIP-Seq (both
histone ChIP-Seq and transcription factor ChIP-Seq) starts with crosslinking DNA-
protein interactions in intact cells. Cells are then lysed, and chromatin is fragmented by
sonication. Immunoprecipitation is used to "pull-down" the DNA-protein complexes of
interest. Protein is then digested and removed, and the DNA is purified. Left: DHS-Seq
starts with digesting intact nuclei with a small amount of DNase I (represented by
scissors in the figure). Open chromatin regions are preferentially digested as a result of
their altered nucleosome structure. Protein is digested, and the DNA is purified and size-
selected by a sucrose gradient. The objective is to isolate the "two-hit" fragments
released by two nearby cutting events. DHS-Seq is an unbiased technique compared to
ChIP-Seq as the former does not rely on preselecting any target for immunoprecipitation.
DNA fragments from both techniques were then prepared for high-throughput sequencing.
Sequences are then mapped to reference genome. Regions that have significantly more
reads than the background are called as enriched regions or peaks. Adapted by
ilk
permission from Macmillan Magazines Ltd: Nature (Giresi and Lieb, 2006), copyright
2006.
1.3.4 DNA sequence motif analysis
The above three approaches (histone modification, transcription factor binding site and
DNase hypersensitivity region profiling) aim to discover both important cis-regulatory
genomic elements and trans-acting factors. The latter are mainly discovered by
performing computational DNA sequence motif analysis on experimentally-identified
cis-regulatory elements. DNA sequence motifs are short and recurring patterns in DNA
that may have biological functions. Examples of these include CpG islands, sites for
ribosome binding and mRNA processing (splicing, editing and polyadenylation). The
motifs that this thesis is concerned with, however, are sites that are bound by trans-
regulators. Readers are referred to detailed reviews on the topic of motif discovery and
analysis (MacIsaac and Fraenkel 2006; Macisaac and Fraenkel 2010). The key point
about computationally-identified trans-regulators is that they need to be experimentally
verified by various methods, such as loci-specific ChIP and electrophoretic mobility shift
assay (EMSA). This emphasizes that understanding transcriptional regulation requires
concerted computational and experimental efforts.
1.3.5 Transcriptional outcomes
The regulatory events described above ultimately serve one main purpose: they regulate
the cell type, the time and the quantity that genes are expressed. The repertoire of
expressed genes in a cell largely determines its cell identity and cellular state.
Transcription profiling has been an important tool for disease classification (Armstrong,
Staunton et al. 2002), prediction (Golub, Slonim et al. 1999), diagnosis (Elashoff,
Wingrove et al. 2011) and therapeutic treatment selection (Tan, Ivanova et al. 2011). It is
also the most widely-used (largely due to its cost and convenience) high-throughput
genome-wide tool for discovering new biology, such as the effect of knocking out a gene
and after a drug treatment, to name a few.
Traditionally, transcriptome profiling has been performed using microarray. This
involves isolating total RNA from cells and reverse-transcribing the mRNA into cDNA,
which are then labeled and hybridized with pre-designed oligonucleotide probes on a
microarray. The quantity of each mRNA can be estimated from the fluorescent intensity
corresponds to the oligonucleotide probes. Recently, RNA-sequencing (RNA-Seq) is
gaining popularity as the method of choice for transcriptome profiling. RNA-Seq does
not require the design of oligonucleotide probes, thus allowing de novo discovery of new
transcripts and profiling of poorly annotated or unannotated genomes and genomic
elements (e.g. long non-coding RNA). It has higher accuracy and sensitivity since it does
not rely on hybridization of cDNA to complementary probes. Strand-specific RNA-Seq
enables direction of transcription to be identified, assisting the identification of anti-sense
transcripts. Paired-end RNA-Seq allows for accurate identification of splicing events.
While ENCODE has come up with a list of guidelines on the experimental aspects of
RNA-Seq (ENCODE 2011), RNA-Seq lags behind microarray in terms of the maturity,
variety, and ease of use of the computational analysis methods; this is partly due to the
more complex nature of RNA-Seq experiments (Mortazavi, Williams et al. 2008).
However, it is expected that RNA-Seq computational analysis methods will improve
rapidly and substantially in the near future.
In the field of adipose insulin resistance, Ruan et al used one of the first
generation microarray to identify several hundred differentially expressed genes upon
TNFa-induced insulin resistance in 3T3-L1 (Ruan, Hacohen et al. 2002). Careful
functional annotation of the differentially expressed genes reveals that TNFa treatment
induces many preadipocyte genes and suppresses many adipocyte important genes. In a
separate study comparing TNFa- and dexamethasone-induced insulin resistance in 3T3-
L1, based on the common genes induced by both treatments, it was discovered that
reactive oxygen species (ROS) is a common mediator of both forms of insulin resistance
(Houstis, Rosen et al. 2006). These examples illustrate the novel biological insights that
transcription profiling can offer.
1.4 Thesis Motivation
The main goal of this thesis is to enhance the understanding of insulin resistance at the
transcriptional level by systems approaches. The advent of high-throughput sequencing
technology has enabled the above-mentioned genome-wide experiments to be carried out
in a cost-effective and timely manner. Each of these experiments interrogates the
transcriptional process through a unique angle. Through these experimental approaches,
in combination with computational analysis, we aim to better understand the adipocyte
system and the transcriptional derangements that occur in adipose insulin resistance.
There are two main studies in this thesis. Chapter 2 describes the characterization
of a particular histone modification mark, H3K56 acetylation, in human adipocytes
through ChIP-Seq. We discover its extensive genomic coverage and its association with
the adipokine signaling and type 2 diabetes pathways, which were previously
unappreciated. In Chapter 3, we turn to the mouse 3T3-L1 system. We set up four
diverse in vitro insulin resistance models in 3T3-L1 and carefully analyze their
transcriptomes with those from diet-induced obese mouse white adipose tissue. We
carefully evaluate the features of in vivo adipose insulin resistance that each in vitro
model captures. Furthermore, by analyzing both the RNA-Seq and DHS-Seq data, we
identify the potential transcription factors regulating the gene induction and gene
repression upon TNF-induced insulin resistance.
On the one hand, the complexity of the human (and mouse) transcriptional
regulation has propelled generations of scientists to dive into the "sea of DNA and
transcription factors" in search for bona fide cis-regulatory elements and trans-acting
factors. On the other hand, the epidemic of metabolic diseases has prompted many
clinicians and researchers to try to understand insulin resistance, the common etiology of
these diseases, more systemically and thoroughly. The original research presented here
represents our efforts to advance the understanding of transcriptional regulation of
adipocyte and adipose insulin resistance in a systems manner; the many cis-regulatory
elements and trans-acting factors that we identified in our studies will hopefully help
fight the war against obesity and metabolic diseases.
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2. Genome-wide profiling of
H3K56 acetylation and
transcription factor binding sites in
human adipocytes
2.1 Summary
This chapter presents the genome-wide profiling of an interesting histone modification,
H3K56 acetylation, in mesenchymal stem cell-derived human adipocytes. H3K56
acetylation has been studied in details in the context of DNA replication and repair in
yeast, but its role in human adipocytes is largely unknown. We are interested in this
particular histone modification in adipocytes as CBP, p300 and SIRT1, proteins that have
been implicated in insulin resistance, regulate H3K56 acetylation status. We found an
unexpectedly extensive H3K56 acetylation coverage throughout the genome in human
adipocytes, and genes with the highest level of H3K56 acetylation are highly related to
adipokine signaling and type 2 diabetes pathways, highlighting the important role of this
histone modification in adipocytes. From DNA sequence motif analysis, we proposed
transcription factors that may be responsible for recruiting the histone acetylases and
deacetylases to the sites of H3K56 modification. Our study is the first genome-wide
profiling of H3K56 acetylation in human adipocytes.
This work was previously published in PLoS One June 2, 2011, Vol 6, Issue 6, page
e19778. It was an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided that the original author and source are credited.
2.2 Manuscript: Lo et al, PLoS One 6(6): e19778
(2011)
OPEN a ACCESS Freely available online PLoS one
Genome-Wide Profiling of H3K56 Acetylation and
Transcription Factor Binding Sites in Human Adipocytes
Klnyui Alice Lo', Mary K. Baudmann, Amy P. Baunann3 , Christopher J. Donahue, Mark A. Thiede3,
Lisa S. Hayes', Shelley Ann G. des Etages, Ernest Fraenskel'e
I Department ofaigical Engineering, Massadnsetts institute of Tedhnology. Cambddge Massachusetts, United States at Ameica, 2Computer Science and Actifical
inteligence Laboratory, Massadasetts Institute of Tedhnology, Carmtuidge, Massachusetts, United States of America 3 Geneticaly Modified Models Researda Center of
Emphasis, P1iw Global Research and Development, Groton, Connecticut, United States of Amerca, 4Catdiovascular, Metabolic and Endocrine Diseases, Pirer Global
Research and Development, Groton, Connecticu, United States of America
Absat
The growing epidemic of obesity and metabolic diseases cals for a better understanding of adipocyte biology. The
regulation of transcription in adipocytes is particulady important, as it is a target for several therapeutic approaches.
Transcriptional outcones are influenced by both histone modifications and transcription factor binding. Although the
epigenetic states and binding sites of several important transcdption factors have been proted in the mouse 3T3-L1 cell
line, such data are lacking in human adipocytes. In this study, we identified H3K56 acetylation sites in human adipocytes
derived fromm esenchymistem cels. 3K56 is acetylated by CP and p300, and deacetylated by SUM, dare proteins with
important roles in diabetes and insulin signaling. We found that while almost half of the genome shows signs of H3K56
acetylation, the highest level of H3K56 acetylation is associated with transciption factors and proteins in the adipokine
signaling and Type N Diabetes pathways. In order to discover the transcdption factors that recuit acetyltransierases and
deacetylases to sites of H3K56 acetylation, we analyzed DNA sequences near H3K56 acetylated regions and found that the
E2F recognition sequence was enrched. Using chiomatin im mnoprecipitation folowed by high-throughput sequencing.
we confimned that genes bound by E2F4, as wel as those by HSF-1 and CEBP. have higher than expected ievels of H3K56
acetylation, and that the transcrption factor binding sites and acetylation sites are often adjacent but rarely overlap. We
also discovered a significant difierence between bound targets of CIEDPa in 3T3-.1 and human adipocytes, highlighting the
need to construct species-specific epigenetic and transcription factor binding site maps. This is the frst genome-wide
profile of H3K56 acetylation, E2F4, C/BEPt and HSF-1 binding in human adipocytes, and wil serve as an important resource
for better understanding adipocyte transcriptional regulation.
Cab=e to KA, Satchmann M , Saumann AP, Donahue CJ. Thiede MA. et at (2011) Genome-Wde Prolling of H3K56 Acetylation and Transcription Factor
Sinding Sites in HIuman Adipocytes. PtbS ONE 660 e19778. doi:1O.1371fjownatpone.0019778
Edhor Marc Tjwa, University of Fraiut-University Hospital Frankfuct, Gennany
nealved October 14 2010; Ac-- Apri IS, 2011; PWbised June 2 201I
Copyright: 0 2011 to et at This is an open-access artide distributed under the terms of the Creative Commons Attriudon License, which permits unrestricted
use, distbxuioi, and reprduction in any medium, provided the original author and source are credted.
Fendin: AJLis supported by the National Science Scholarship from Agency of Scence, Tedmology and Research. Singapore. EF. is the recipient of the Eugene
Bel Career Development Chair. This wwk used computing resources funded by the Nadonal Science Foundation under Award No. D0-0821391. This research
was funded by Pier lnc., and the co-authors who are Pfizer employees were involved in the study design, data colection and analysis, decision to publish, and
preparaton of the manusaipt.
Campeavg inrests: MMB APB MAT LH and SGD are Pfber Inc. shareholders. This does not alter the authoWs adherence to ail the PLoS ONE policies on sharing
data and materials.
* E-mat fraered-admin@itkdu
White adipose tissue is a key organ in the regulation of whole
body energy homeostasis [1]. Besides acting as a passive fat storage
organ, it serves to regulate systemic energy homeostasis by
secreting various soluble mediators, widely termed adipokines.
examples of which include leptin, adiponectin, visfatin and resistin
[2]. It has been recognived that an increase in white adipose tissue
mass is associated with insulin resistance, a major cause of
diabetes, hypertension and cardiovascular diseases. With the
growing epidemic of obesity, a better understanding of adipocyte
biology could potentially lead to novel drug targets to tadke
obesity-related metabolic diseases,
Transcriptional controls have emerged as a particularly
important aspect of cellular regulation that can be exploited for
therapeutic benefit in diabetes. Both the most widey prescribed
antd-diabetic treatment, metformin, as well as the more recently
developed thiazolidinediones act by modulating the activity of
transcriptional regulatory proteins J3,4]. Recent advances in high-
throughput technologies now provide methods for examining
transcriptional regulation across the genorne, potentially revealing
key transcriptional regulators that could serve as potential drug
targets. For example, chromatin immunoprecipitation followed by
microarray analysis (ChIP-chip) or next generation massively
parallel sequencing (ChlP-seq) can be used to probe genome-wide
DNA-protein interactions. Currendy, most of the ChIP-chip or
ChP-seq experiments on adipocytes have been done in cell lines
of murine origin such as the preadipocyte cell line 3T3-LI [5,6,7].
Given that tissue-specific transcription has diverged significantly
between human and mouse [8], there is a need to construct a
human adipocyte transcriptional regulatory network.
Changes in histone acetylation appear to have a central role in
insulin function and insulin resistance. Both insulin and metforTin
have been shown to alter the activity of the histone acetyhrans-
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ferases (HATs), CBP and p30 0 [9]. In addition, although CBP
heterozygous mice are lipodystrophic, they are protected from
diet-induced insulin resistance [10]. Furthermore, the histone
deacetylase (HDAC) SIRTI, by virtue of its role in inflammatory
responses, adipokine secretion and its interaction with the insulin
signaling pathway, is suggested to have therapeutic benefit in
treating insulin resistance [11]. Recently, it has been shown that
the lysine 56 of histone H3 (H3K56) is acetylated by CBP and
p300 and deacetylated by SIRTI and SIRT2 [12]. Given the roles
that HATs and HDACs play in controlling insulin sensitivity, and
that the H3K56 acetylation status is a consequence of the
combined activity of HATs and HDACs, we measured the
genome-wide distribution of H3K56 acetylation in normal human
adipocytes.
The presence of H3K56 acetylation has only been recently
discovered in humans [12], therefore the molecular function and
significance of H3K56 acetylation in humans is less studied than in
yeast. It has been shown that in human embryonic stem cells prior
to differentiation, H3K56 acetylation marks targets of the key
regulators of pluripotency, namely NANOG, SOX2 and OCT4
[13]. Upon cellular differentiation, H3K56 acetylation relocates to
developmental genes.
In this study, we measured sites of H3K56 acetylation across the
genome in mature adipocytes derived from human mesenchymal
stem cells (hMSC) [14], which provide a good it vir model to
study protein-DNA interaction in human adipocytes and compl-
ment the more widely used mouse cell lines 3T3-L1 and 3T3-
F442A. We showed that in these cells, H3K56 acetylation is
associated with ahnost half of the genome and it primarily occurs
around transcription start sites. Genes with this modification were
generally associated with higher expression, and genes with the
highest levels of H3K56 acetylation are enriched for transcription
factors, adipokine signaling and diabetes-related proteins. We used
computational methods to identify DNA-binding proteins that
might recruit acetyhransferases and deacetylases to the sites of
H3K56 acetylation. We found a strong enrichment of the E2F
motif in these regions and demonstrated using ChIP-seq that E2F4
binds many of these lc. ChIP-seq analysis also showed that the
majority of HSF-1- and C/EBNt-bound genes are enriched for
H3K56 acetylation. At sites where the H3K56 acetylation
modification and transcription factor binding co-occur, H3K56
acetylation is usually adjacent to but not directly overlapping the
transcription factor binding sites. These data provide the first
genome-wide view of H3K56 acetylation in human adipocytes,
paving the way for future studies aimed at understanding how
epigenomic modifications influence obesity-related diseases.
Results
Differentiation of mature human adipocytes
Since we are interested in studying transcriptional regulation in
human adipocytes, we derived mature adipocytes from human
bone marrow mesenchymal stem cells purchased from Ionza.
Differentiation took 19 days, including 14 days in adipogenic
differentiation media and 5 days in adipogenic maintenance media
(see Methods for details). Figure 1A shows that before differen-
tiation, cells exhibit an elongated and fibroblast-like morphology.
After differentiation, cells become more round and accumulate
multiple intracellular lipid droplets. Using the Celomics high
content imaging system, we determined the differentiation
efficiency of replicate samples of 6 independent differentiation
experiments (Table SI) with cells from different passages (only cells
less than passage 8 were used). We estimated that the
differentiation elliciency was 61% -4 %, as determined by the
number of cells that have intracellular lipid droplets (stained by
Nile red) over the total number of nuclei observed (stained by
DAPI). Cellomics data also show that about 54% of the cels were
positive for the adipocyte marker, PPARy, and that the PPARt
staining largely overlaps with that of DAPI (Figure IB), as
expected for mature adipocytes. We developed a purification
process to separate mature adipocytes, which are buoyant during
centrifligation, from immature adipocytes, which pelet. Based on
visual examination under the microscope, our adipocyte prepara-
tion appears to be at least 90% mature adipocytes.
Overall analysis of H3K56 acetylation sites
After crosslinking the mature adipocytes using formaklehyde
which captures m. mv protein-DNA interactions, we performed
chromatin immunoprecipitation with an antibody that specificay
targets the acetylated lysine 56 of histone 3. The specificity of the
antibody for this particular histone acetylation site has been
previously shown in ChIP experiments and other applications
[12,15,16]. Immunoprecipitated protein-DNA complexes were
reverse-crosslinked, purified DNA was sequenced using the
Illumina Genome Analyzer II, and the resulting sequences were
used to identify enriched regions as described in Materials and
Methods. A gene was considered to have H3K56 acetylation if
there was at least one ChiP-seq peak within 10 kilobases of the
transcription start site. The 10-kilobase window was chosen in
light ofa recent report showing that a regulatory site's influence on
expression falls off almost linearly with distance from the nearest
transcription start site in a 10-kilobase range [17]. The number of
reads, peaks and genes bound/enriched for each ChIP-seq
experiment performed is listed in Table S3.
Using these criteria, we found that 10,215 genes have H3K56
acetylation. While the majority of the H3K56 acetylation sites
occur at the proximal promoter region (Figure 2A), there is a drop
in H3K56 acetylation right before transcription start sites (Figure
Sl). The same observation has been made on genome-wide data
for other histone modinfications such as H3K4me2 and H3K4me3
in hematopoietic cels [18]. These findings suggest that there is a
depletion of nucleosomes immediately upstream to transcription
start sites.
Genes enriched for H3K56 acetylation are also targets of
three different transcription factors
In order to discover the DNA-binding proteins that recruit
acetyltransferases and deacetylases to sites of H3K56 acetylation,
we searched for the DNA sequence motif associated with the
H3K56 acetylation-enriched regions using the THEME algorithm
[19]. The top motif obtained was that of E2F (Figure 2B),
suggesAing that members of this family of proteins might bind to
these loci. To verify ds, we performed ChIP-seq on the cell cycle
regulator E2F4. E2F4 was found to bind to 5,340 genes, of which a
very high proportion (87%) was also enriched for H3K56
acetylation. We not only found that H3K56 acetylation and
E2F4 binding occur at a similar set of genes, we also found that the
acetylated and binding locations are usually close to each other,
with 74% of E2F4 binding sites occurring within 300 base pairs of
an H3K56 acetylation site (Table S4). The genomic distribution of
E2F4 was highly similar to that of H3K56 acetylation (Figure 2A),
with the majority of the sites proximal to transcription start sites.
The frequent association of E2F4 binding and H3K56 acetylation
supports the hypothesis that E2F4 recruits HATs and HDACs to
these sites.
HATs and HDACs also modify DNA binding proteins in
addition to acetylating and deacetylating histones respectively It is
interesting that three of the proteins known to aher acetylation of
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Fig 1. knages of bon. Unar nwmnesnchy-4a s 1 Mels beore and after adlpogencd nimtlon. (A) The left panel shows 4x phase
contrast microscope images of wnineeniated human bone marrow mesenchyma stem cels and the night panel shows the differentiated
adipocytes at day 19. (8) Cenomics image analysis of the human bone manow mesenrchymal stem cels-deried adipocytes after 19 days of
d ion, fixed and stained with DAP (nuclei-bluel Nile red (a selective fuorescent stain for intracelular lpid droplets-yeilow), and specifc
antibodies for PPARy (Alexa 647-magenta. The left panel shows the lpid and nucei staining and the ight panel has additional PPARy staining, three
of which are indicated with red anows.
doi:101371rgoumapone.001977&g001
H3K56, namely CBP, p300 and SIRTI, are also known to
acetylate and deacetylate the master regulator of heat shock
response, HSF-1, affecting its DNA binding activity and
expression of its target genes 1201. In order to determine if HSF-
I and H3K56 acetylation share similar target genes, we performed
ChIP-seq on HSF-I. Our genome-wide HSF-I data show that in
mature human adipocytes, HSF-I binds to 174 genes, 90% are
also enriched with H3K36 acetylation and 69% of the peaks
associated with HSF-l-bound genes are within 300 base pairs of
an H3K56 acetylation site.
E2F4 and HSF-1 are ubiquitously expressed transcription
factors, whose functions appear to be conserved across many
tissues, raising the question as to whether H3K36 acetylation
might also be associated with the binding of adipocyte-specieic
proteins. To explore this question, we profiled the genone-wide
binding sites of the master regulator of adipocytes, C/EBPo.
C/EBPa binds to 5,818 genes, of which 74% also have an H3K56
acetylation mark The complete list of genes that have H3K56
acetylation and are also bound by at least one transcription factor
is listed in Table S5.
In order to verify the acetylation and transcription factor
binding sites identified by the above four ChIP-seq expeiments,
we selected 21 positive regions and 2 negative regions to perform
independent ChIP-qPCR experiments (Figure S2) in biological
- 47
- S ONE I wwwplosone-rg 3
tdplicates. We found that among the 21 positive loci tested, 20
show significant enrichment when compared to the IgG controL
The 2 negative control regions show no enrichment in all the
ChIP-qPCR experiments performed.
When we examined the percent of overlap between H3K56
acetylation sites and the binding sites of the different transcription
factors, we noticed that while HSF-1 and E2F4 are very often
recruited to regions where H3K56 acetylation occurs, this is not as
common for C/EBPac only 31% of the peaks associated with the
C/EBPx-bound genes are within 300 base pairs of an H3K36
acetylation site. Furthernore, in contrast to the enriched regions of
E2F4 and H3K56 acetylation, C/EBPM-enriched regions have a
more dispersed distribution throughout the 10-kilobase window
around transcription start sites (Figure 2A), and a large proportion
of C/EBPoz peaks (79%) lies beyond 10 kilobases from transcrip-
tion staut sites. The more widespread distribution of C/EBPf
binding sites agrees with the study by Lefterova d a [6]. When we
compared our C/EBPt data set with a recently published PPARl
ChP-eq data set in human adipose stromal cells derived
adipocytes [21] , 43% of the C/EBPot-enriched regions (14,174
out of 32,864) overlapped with the PPARy-enriched regions, while
a previous study comparing C/EBPft and PPARy ChIP-chip data
in 3T3-LI [6] using promoter arrays shows that the two factors
share 63% of their binding sites. The lower percentage of overlap
June 2011 1 Volume 6 j Issue 6 1 e19778
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A H3K56ac
iI -
-10000 + 10000
E2F4
-10000 0 10000
40-
HSF-1
8-
8 -
8 -
8-I iiii
-10W 0 10000
C/EBPa
I
-10000 0 10000
Distance fforn transcription start sites (bp)
ChIP Motif CV error P-value Motif Logo
H3K56ac E2F 0.36 <le-15
E2F4 E2F 0.33 <le-15 P
HSF-1 HSF 0.22 <le-15
C/EBPa C/EBP 0.27 <1e-15
r
Figure 2. Genme-wle analysis of H3KS6 acty ion and trmanscripon factor Andng In humn adpocyts. (A) Histograms showing
that the disibuiom of peaks for al four ClP-seq experiments are centered on transcription start sites the X-ais represents cstane from
transcription start sites and the Y-axis represents frequency. H3K56ac is H3K56 acetylation (B) Sequence motifs associated with the enriched regions
in each ChIP-seq exwerimen Only the highest ranked motif is shown. Cross-vaidation errors (CV eror5 ) and p-values were calculated as described in
MethodL.
dot10.1371fprjomapone.009778.g002
in human adipocytes could be due to species differences and we
are comparing C/EBPat and PPARy binding sites in two different
human adipocyte systems; it could also be because the ChIP-seq
technology recoves many more distal binding sites.
Bound genes are associated with higher expression
Histone acetylation is generally found to be associated with gene
activation, while particular DNA-binding proteins can either
activate or repress transcription. We compared our data to gene
expression data from mature human adipocytes (Des Etages, S. et
al manuscript in preparation) and found that genes with H3K56
acetylation are associated with higher expression (Figure 3A).
However, similar to what has been observed in human embryonic
stem cells 1131, H3K6 acetylation marks are not restricted to
highly expressed genes; some unexpressed or poorly-expressed
genes also harbor this modification, suggesting that H3K56
acetylation is not simply a marker for gene activity. We divided
genes that have H3K36 acetylation based on the distance from
their transcription start sites to the nearest acetylation site. We
found that genes with one or more H3K56 acetylation sites within
2 kilobases of transcription start sites have significandy higher level
of expression compared to the unmodified genes or genes with the
modification further away from transcrption start sites (p-
value<le-15; Figure 3B). Similarly, genes that are bound by
E2M4, HSF-I or C/EBPor are also associated with higher
expression (Figure &A). The differences of the expression
Aune 2011 1 Voume 6 k Issue 6 e19778.PLoS ONE I wwwplosone~org
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Genome-Wide Profiling in Human Adipocytes
Figure 3. Genes that are bound by transarption factor or acetylated at H3K56 are assoated with higherexpmslnn (A) Comparison
of the expression level of all genes Oeft paneD to genes that have (red) or do not have (blue) H3K56 acetylation or transcription factor binding sites.
The dark band in the middle of the each box represents the median expression value of all gene that haveido not have an H3K56 acetylation or
transcription factor binding sites. Asterisks represent statistical significance with p-values<1e-16. (B) The top panel shows the distriition of
expression values for genes that have been categoried based on the distance from their transcription start sites to the nearest H3Ks6 acetylation
peak.The number within each box represents the number of genes in each category. The bottom panel is similar to the top one, zooming In around -
1000 to +1000 base pair window.
do0.1371fjournaLpone.0019778.g0 3
distributions between bound and unbound genes fkr all the
transcription factors under study are highly significant (p-
value<le-15).
Many genes for adipocyte transcription factors are highly
acetylated at H3K56
Our genome-wide H3K56 acetylation data reveal that a
surprisingly large number of genes (10,215) are enriched for this
histone modification. We hypothesized that genes with very high
levels of acetylation might be functionally distinct from those with
lower levels of acetylation. Indeed, when we ranked the genes with
H3K56 acetylation by the number of acetylated sites per gene, we
found that 47 of the top 161 genes (all of which have five or more
H3K56 acetylation sites) are annotated as transcription factors, (p-
value: 3.5e- I1) and twelve of them are from the homeobox
structural class (EMX2, HOXAI0, HOXA9, HOXB2, HOXC9,
IRX5, LMO4, MEISI, MEIS2, PRRXI, SATB2 and SIX2; p-
value: 4.8e-7). Many homeobox transcription factors are involved
in the control of gene expression during morphogenesis and
development, and some of them have been shown to have
important roles in the differentiation of adipocytes [22]. This
observation is in agreement with the observation that develop-
mental genes are hyperacetylated at H3K56 in differentiated cells
[131. Other important adipocyte-related transcription factor genes
that are hyperacetylated include CEBPA, CEBPB, CEBPD,
KLF6, KLF9, FOXC1, IRF), PPARA, RXRA and THRA
(Figure 4A).
To search more systematically for classes of genes with high
levels of H3K56 acetylation, we ranked the 10,215 genes with
H3K56 acetylation by the number of H3K56 acetylation sites per
gene. Gene set enrichment analysis [23] identified a number of
gene sets that were overrepresented at the top of this list, including
the KEGG adipokine signaling pathway and the KEGG type II
Diabetes Mellitus (T2DM) pathway (Figure 4B). Thus, high levels
of H3K56 acetylation may be associated with regulation of
adipokine secretion and the etiology of T2DM. All the gene sets
that have a family-wise error rate (FWER) of less than 0.05 are
listed in Table S7.
C/EBPa-bound targets are enriched for lipid metabolic
genes and adipokines
The genome-wide binding data of C/EBPa recovered many
known regulatory sites on genes that are important in adipogenesis
and adipocyte function, including FABP4/aP2, a fatty acid
binding protein; CD36, a regulator of fatty acid transport,
LIPE/HSL, an enzyme that regulates hormone-mediated lipolsis
OLRI, a low density lipoprotein receptor, and MEl, an enzyme
that generates NADPH for fatty acid biosynthesis. The top gene
ontology (GO) category that is associated with the C/EEPa-bound
genes is lipid, fatty acid and steroid metabolism (p-value: 4.3e-4,
Table S8). As previously reported, C/EBN1 regulates transcription
of the human adiponectin gene through an intronic enhancer [241.
We were able to confirm the existence of such an enhancer in our
model of hMSC-derived adipocytes (Figure S3). In addition, we
also observed C/EBIer binding sites on the resistin promoter and
retinol-binding protein 4 (RBP4) promoter, suggesting that C/
EBl may have a role in mediating the expression of adipokinm
The human C/EBlN gene is almost 90% homologous to its rat
and mouse counterparts [251, Because of this high degree of
homology, we asked if the majority of the human C/EBPl-bound
genes are also bound in mouse. To determine the degree of
conservation of C/EBlN binding between human and mouse
adipocytes, we compared our C/EBPl ChIP-seq data with the
published C/EBlN ChIP-chip data in 3T3-L1 [6]. There are
3,998 C/EBll-bound genes in 3T-L, out of which 3,345 have
human orthologues We found that 48% (1,636 out of 3,345) of the
C/EBle targets in 3T3-Ll are also targets in human adipocytes
Most (72%, 4,182 out of 5,818) of the human adipocyte C/EBP2
target genes are unique- Some of the differences between these
data sets are undoubtedly due to the fact that they were collected
with different experimental techniques However, the data are also
consistent with the observations that binding sites have diverged
significandy between human and mouse for several other highly
conserved transcription factors [8].
HSF-1 binds to classic heat shock protein genes in
unstimulated human adipocytes
HSF-I is a transcription factor induced by diverse environmen-
tal and physical stresses. Our experiment provides the first
comprehensive view about the role of HSF-I in human adipocytes.
The genome-wide HSF-I data show that in mature adipocytes,
HSF-I binds to 174 genes, examples of which are DNAJB6,
HSPHI, HSPA9, HSPDI, HSPBI, CCT4 and CCT7; many of
the bound genes are involved in protein folding (p-value: 8Ae-1 7)
protein metabolism and modilication (p-value: 2.2e-8), protein
complex assembly (p-value: 2.9e-5) and stress response (p-value:
2.8e-4) (Table S8). This finding highlights the fact that even in
unstimulated and unstressed adipocytes, HSF-I binds DNA. This
is the first time that HSF-1 binding sites have been profiled in
human adipocytes, It will be interesting to compare HSF-I
binding sites in other quiescent tissues under non-heat shock
conditions.
E2F4 targets in human adipocyte are highly enriched for
cell cycle genes
We found that in human adipocytes, E2F4 binds to many genes
(5,340) that have not previously been recognized as its targets; the
majority of the binding sites are located proximal to transcription
start sites: 83.5% and 6L9% are located less than 1000 and 100
bases from transcription start sites, respectively. The top GO
categories associated with the E2F4-bound genes are DNA
metabolism (p-value: 5.le-14), cell cycle (p-value: Lle-15) and
chromatin packaging and remodeling (p-value: 5.0e-9) (Table S).
True to its role as a cell cycle regulator, E2F4 binds to many of the
wel-known cyc endent kinases (CDK2, CDK4, CDK5) and
cyclin-dependent kinase inhibitors (CDKNIA, CDKNIB,
CDKNIC, CDKN2A, CDKN2C, CDKN2D and CDKN3) in
human adipocytes,
In order to assess the differences in binding among different
human tissues. we compared our E2F4 ChIP-seq data in
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Figure 4. Genonic maps of ea..mples of H3K56 acetyition-erihed genes. (A) H3K56 acetylation moclications were found on the
promoters and gene body of C/EBit CIEBP3 and CJEBP& Background represents the mock IgG experiment reada Rectangular boxes below the
H3K56 acetylation peaks represent the enriched regions. The Y-axis represents the number of reads per millon sequenced, note that each ChP
experiment was plotted on a dillerent scale on the Y-axis. Arrows indcate the ckection of transcriptior (B) Profiles from gene set erichnment
analysis. Left HSA4920 Adiocytokine signabng pathway. ight 1AD4930 Type I Diabetes Mekus. Genes were ranked based on the number of
acetylated sites per gene Black lies represent genes with the specified annotaton. The Y-axds represents the enrichment score (see 1231
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adipocytes with the published E2F4 ChIP-chip data in human
liver, pancreatic islets, pancreatic acinar tissues and the liver
carcinoma cell line HepG2 [26]. Using promoter arrays capturing
up to I kilobase immediately upstream of most transcription start
sites, Conboy d .L found that there are 441 genes common among
the four human tissues/cell types. We found that among these 441
genes, ahnost half (195 genes) were bound by E2F4 in adipocytes.
A large proportion of the common genes were related to the cell
cycle process (60 out of 199, p-value: 5.02e-14), in accord with the
previous finding that cell cycle genes are the conserved targets of
E2F4 [26].
Transcription factor binding sites and H3K56 acetylation
marks are often adjacent but do not overlap
Comparing the genome-wide H3K56 acetylation distribution
with the binding sites of C/EBNt, HSF-I and E2F4, we found that
the majority of the genes that are bound by each protein are also
acetylated at H3K56 (p-value< Ie-15, Table S4). The fraction of
the transcription factor binding sites that is within 300 base pairs of
a site of acetylation ranges from 31% to 74%. Despite the
proximity of these sites, we fiund that transcription factor binding
sites rarely occur at exactly the same location as the strongest sites
of acetylation. An example is illustrated by the DUSPI gene,
which has mutiple H3K56 acetylation sites at the promoter and
gene body (Figure 5A). It also has C/EBPtw, E2F4 and HSF-1
binding sites within 2 kilobases from the promoter. Figure SA
shows that C/EBlN and HSF-1 bind at the same genomic
location, and E2F4 binds closer to the transcription start site.
However, none of the binding sites of the above three transcription
factors overlap with the H3K56 acetylation regions. On the
genome-wide level, we examined genes that have H3K56
acetylation as well as E2F4 and C/EBft binding sites within
1500 base pairs of each other (we excluded the HSF-I data as
HSF-l only binds to less than 200 genes genome-d). For each
region, we computed the pairwise correlation coefficient of
binding location between transcription factors and between each
transcription factor and H3K56 acetylation (see Methods). E2F4
and C/EBPle binding locations often show positive correlation,
and a significant number even have a perfect correlation with
r= 1, suggesting that the binding sites directly overlap one
another. On the other hand, E2F4 and H3K56 acetylation rarely
exhibit perfect correlation and they are often negatively correlated
(Figure 5B). We display the ChIP-seq enrichment signal across
1500 base pairs, center around the strongest E2F4 peak in a
heatmap format (Figure SC). The heatmap clearly illustrates that
binding of E2F4 and C/EBlt often occur at identical genomic
loci, but this is not the case for E2F4 and H3K56 acetylation.
The binding of transcription factors and the modification of
histones are highly interdependent processes that together
determine the epigenetic state of the cell and regulate gene
expression. A more thorough enumeration of genomne-wide
transcription factor binding sites and histone modifications,
combined with gene expression analysis, could lead to a better
understanding of how gene regulation occurs. This systems
. . 52
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approach could be of great use in identifying better mechanisms
for manipulating transcription for therapeutic purposes
We have presented the genome-wide locations for the
acetylation of H3K56, a histone modification regulated by CBP,
p300 and SIRTI, all of which have been implicated in insulin
resistance. To better understand the mechanism by which these
histone modifying enzymes are recruited to these loci, we used
sequence analysis to discover motifs that are overrepresented near
sites of H3K56 acetylation. We observed enrichment for the
binding sequence for E2F proteins and used ChiP-seq to confirm a
dramatic enrichment of E2F4 bound genes at H3K56 acetylation
regions. Surprisingiy, we found that the binding sites of two other
transcription factors, HSF-I and C/EBPt, also show a significant
degree of overlap with the sites of H3K56 acetylation CTable S4).
Approximately 70% of the binding sites fkr each of HSF-I and
E2F4 and approximately 30% of the C/EBPz sites are within
three hundred bases of a site of H3K56 acetylation. The very high
frequency of H3K56 acetylation near HSF-I and E2M4 raises the
interesting possibility that these two proteins may recruit the
acetylase(s) that modifies H3K56. It is interesting that transcription
factor binding and H3K56 acetylation generally do not occur at
the exact same genomic location. This probably reflects the fact
that the transcription factors we have examined cannot bind to
DNA that is wrapped around the histone core. In contrast, E2F4
and C/EBPlt can be found in much closer proximity to each
other.
Genes that are bound by one or more factors or harbor the
particular H3K56 acetylation modification are associated with
higher expression levels, reflecting the general role of these
transcription factors and histone modification in gene activation.
Although H3K56 acetylation is widespread in human adipocytes,
the genes that have the highest levels of acetylation are enriched
for particular functions, including transcriptional regulation and
adipokines and diabetes-related pathways. Many of the transcrip-
tion factors with high levels of H3K56 acetylation have not been
associated with adipocytes before. it is worth investigating the role
of these transcription factors in adipocyte function.
Mikehsen ed a recently profiled the genome-wide binding sites
of PPARy, CTCF and six histone modifications, namely
H3K4mel, H3K4me2, H13K4me3, H3K27me3, H3K27ac and
H3K36me3 in human adipose stromal cells (hASCs) derived from
aduh subcutaneous lipoaspirates [21]. We noticed that our H3K56
acetylation profile closely mirrors the open chromatin marks
H3K4me2 and H3K27ac that they profiled, with 90% and 87%
overlap, respectively. H3K56 acetyiation has the least overlap (8%)
with H3K27me3, which represents polycomb-mediated repres-
sion. Interestingly, the overlap of H3K56 acetylation with
promoter initiation mark H3K4me3 is a moderate 55%, implying
that H3K56 acetylation is more of an open chromatin mark rather
than a transcription initiation mark
Regarding the physiological role of H3K56 acetylation, recent
work in Sirt6 knock-out mice reveals the association between
hyperacetylation of H3K56 and obesity [16]: neural specific Sirt6-
deleted mice have adult-onset obesity, and they show hyperace-
tylation at H3K9 and H3K56 in various brain regions [16]. The
extent of H3K56 hyperacetylation is particularly widespread; it
was observed in whole cell extracts from hypothalamus, cortex,
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ChIP-qPCR experiments
ChIP experiments for H3K56 acetylation, E2F4, HSF-l and C/
EBPct were performed as described above using separate adipocyte
preparations. We chose 21 positive loci and 2 negative loci to
verify the ChIP-seq peaks by qPCR. Enrichment was measured
using SYBR Green I master mix in the Light Cycler 480
instrument (Roche) by comparing the percent input of the ChIP
sample versus that of the IgG control sample, performed in
triplicate using standard t-test. Only amplified products with a CP
(crossing point) number of less than 33 were considered as positive.
Primers sequences used for qPCR analysis were designed by
oligo7, blasted against hgl8 and a melt curve was generated for
each reaction to make sure that only one product was amplified.
Primer sequences are in Table S6.
ChIP-seq data processing and peak calling algorithm
Unique sequences from each ChIP-seq experiment were
extended 200 base pairs in a strand specific manner and allocated
to 25-basepair bins across the genome. Peaks calling was done as
described [28]: genomic bins containing statistically significant
ChIP-seq enrichment were identified by comparison to a Poisson
background model, using a p-value threshold of 10-9. The
minimum number of counts in a genomic bin required for each
sample to meet this threshold was calculated; they are 12, 8, 10
and 8 for H3K56 acetylation, C/EBPoc, E2F4 and HSF-1
respectively. Bins that are within 200 bases of each other were
combined to form regions. In order to take into account of the
non-random nature of the background reads, an empirical
background model was obtained from a mock IP experiment
using IgG. We required that enriched regions have more than
three-fold greater ChIP-seq density in the specific IP sample as
compared with the non-specific IgG sample, normalized for the
total number of reads. The raw data are deposited in GEO with
accession number GSE24326.
Gene expression analysis
Frozen cells were resuspended in Qiagen RLT buffer and total
RNA isolated using the Qiagen RNeasy Kit. RNA was submitted
to GeneLogic for cRNA preparation using the Affymetrix
Genechip IVT Kit and hybridization to Affymetrix U133 Plus
2.0 microarrays. Expression raw data were processed using the
Robust Multichip Average (RMA) R package in Bioconductor
(http://bioconductor.org). During this processing, only the perfect
match (PM) probe data were used; the mismatch (MM) probes
were not used. The RMA processing consisted of background
correction, quantile normalization to remove deleterious system-
atic effects between arrays and median polish used to estimate
expression values and an additive model fit on log2(PM) values.
The raw data are deposited in GEO with accession number
GSE24422. All data is MIAME (Minimum Information about a
Microarray Experiment) compliant.
Gene ontology and pathway analysis
Gene Ontology analysis was done using PANTHER [29] and
DAVID [30,31]. Redundant GO categories were removed. All p-
values presented were corrected for multiple hypothesis testing.
Motif discovery method
Over-represented transcription factor motifs were identified in
each experiment using THEME [19]. THEME uses principled
statistical methods to test hypotheses about the binding specificity of
the immunoprecipitated protein. Hypotheses are position weight
matrix representations of DNA sequence motifs in the TRANSFAC
PLoS ONE I www.plosone.org
and JASPAR database. They were evaluated based on their cross-
validation error, which represents their ability to predict which
sequences from a held-out test set were bound by the protein and
which were not. Each hypothesis was either accepted or rejected
based on a p-value, which was derived from comparing its
predictive value to those of motifs derived by applying the same
algorithm to randomly selected sequences for 25 times.
Computation of correlation between ChIP-seq peaks
We identified regions of 1500 base pairs that contained binding
sites peaks in the E2F4, C/EBPa and H3K56 acetylation data sets,
where each region is centered around the E2F4 peak. For each
enriched region, we computed three vectors, each represents the
number of reads in one of the three datasets in 1 00-basepair bin,
normalized by the total number of reads sequenced. These vectors
were used to compute the correlation coefficient in figure 5B and
are clustered and visualized as heatmaps in figure 5C.
Supporting Information
Figure S1 H3K56 acetylation enrichment is lower
immediately before transcription start sites. The top
panel shows the normalized enrichment level of H3K56
acetylation with respect to transcription start sites from -10
kilobases to +10 kilobases in 100-basepair genomic bins. The
normalized enrichment level in each genomic bin was computed
by merging the reads across all genes, divided by the maximum
number of reads in any genomic bin. The bottom panel is same as
the top one with higher resolution around -1 kilobase to +1
kilobase with respect to transcription start sites.
(TIF)
Figure S2 ChIIP-qPCR verification of binding sites
identified by ChIP-seq experiments. Positive regions
identified by ChIP-seq are indicated with *; positive regions verified
by ChIP-qPCR are indicated with #. FP represents false positive
and FN represents false negative. Y-axis shows percent of input and
X-axis shows the particular ChIP experiment. (A) Selected H3K56
acetylation regions identified by ChIP-seq. (B) Selected bound
regions identified by E2F4 ChIP-seq. (C) Selected bound regions
identified by HSF-1 ChIP-seq. (D) Selected bound regions identified
by C/EBPa ChIP-seq. (E) Selected bound regions identified by
multiple ChIP-seq experiments. (F) Negative control.
(TIF)
Figure S3 C/EBPa binds to adiponectin promoter and
intronic enhancer. Profile of C/EBPCE binding sites along the
adiponectin gene as shown on UCSC genome browser. Back-
ground represents the mock IgG experiment reads. Rectangular
boxes below the C/EBPa peaks represent the enriched regions.
The Y-axis represents the number of reads per million sequenced.
The arrow indicates direction of transcription. Notice that there is
a strong C/EBPa binding site upstream of the adiponectin
transcription start site, a site that lies exactly at the transcription
start site and another site (circle in red) that lies in the middle of
the first intron, which has previously been identified as an intronic
enhancer.
(TIF)
Table 81 High content image analysis results of the
differentiation efficiency of replicates of 6 MSC-derived
adipocyte cultures.
(XLSX)
Table S2 Antibodies used in this study.
(DOCX)
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Table S3 Number of reads, peaks and genes bound/
enriched for each ChIP-seq experiment.
(DOCX)
Table S4 Number and percentage of genes with H3K56
acetylation and also bound by a particular transcription
factor.
(DOC)
Table S5 List of genes that have H3K56 acetylation and
also bound by at least one transcription factor.
(XLSX)
Table S6 Primer sequences used in this study.
(XLSX)
Table S7 Gene set enrichment results with a family-
wise error rate of less than 0.05.
(DOCX)
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Figure 2-6 H3K56 acetylation enrichment is lower immediately before transcription
start sites
The top panel shows the normalized enrichment level of H3K56 acetylation with respect
to transcription start sites from -10 kilobases to +10 kilobases in 1 00-basepair genomic
bins. The normalized enrichment level in each genomic bin was computed by merging
the reads across all genes, divided by the maximum number of reads in any genomic bin.
The bottom panel is same as the top one with higher resolution around -1 kilobase to +1
kilobase with respect to transcription start sites.
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Figure 2-7 ChIP-qPCR verification of binding sites identified by ChIP-Seq
experiments
Positive regions identified by ChIP-Seq are indicated with *; positive regions verified by
ChIP-qPCR are indicated with #. FP represents false positive and FN represents false
negative. Y-axis shows percent of input and X-axis shows the particular ChIP
experiment. (A) Selected H3K56 acetylation regions identified by ChIP-Seq. (B)
Selected bound regions identified by E2F4 ChIP-Seq. (C) Selected bound regions
identified by HSF-1 ChIP-Seq. (D) Selected bound regions identified by C/EBPa ChIP-
Seq. (E) Selected bound regions identified by multiple ChIP-Seq experiments. (F)
Negative control.
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Figure 2-8 C/EBPa binds to adiponectin promoter and intronic enhancer
Profile of C/EBPa binding sites along the adiponectin gene as shown on UCSC genome
browser. Background represents the mock IgG experiment reads. Rectangular boxes
below the C/EBPa peaks represent the enriched regions. The Y-axis represents the
number of reads per million sequenced. The arrow indicates direction of transcription.
Notice that there is a strong C/EBPa binding site upstream of the adiponectin
transcription start site, a site that lies exactly at the transcription start site and another site
(circle in red) that lies in the middle of the first intron, which has previously been
identified as an intronic enhancer.
Table 2-1 High content image analysis results of the differentiation efficiency of
replicates of 6 MSC-derived adipocyte cultures
Nuclei
Count/ % St.
Culture # Passage # # of wells Fieldsl Well Well Adipocytes Dev.
1 6 8 100 2859 63% 2%
6 8 100 3177 62% 2%
2 6 8 100 2577 59% 3%
6 8 100 2293 65% 10%
3 7 8 100 2701 56% 2%
7 8 100 2655 52% 2%
4 6 11 100 2003 63% 3%
6 11 100 2189 55% 4%
5 6 16 100 2130 57% 3%
6 8 100 3463 67% 9%
6 6 8 100 3280 68% 4%
5 10 100 2640 68% 2%
Table 2-2 Antibodies used for each experiment
H3K56
acetylation
Epitomics 2134-1 YE101702C-2
C/EBPa Santa Cruz Biotechnology sc-9314X F1609
E2F4 Santa Cruz Biotechnology sc-1082X A2909
HSF-1 Santa Cruz Biotechnology sc-9144 L0407
IgG Santa Cruz Biotechnology sc-2027 J2909
Table 2-3 Number of reads sequenced, peaks and genes bound/enriched for each
ChIP-Seq experiment
Experiment Number of Number of Number of Number
reads peaks peaks in of genes
window*
H3K56 6,692,251 20,827 15,081 10,215
acetylation
C/EBPa 3,222,053 32,864 6,853 5,818
E2F4 4,102,521 6,193 4,658 5,340
HSF-1 1,425,586 332 135 174
*window is defined as 10 kilobases upstream or downstream of transcription start sites.
The raw data are deposited in GEO with accession number GSE24326.
Table 2-4 Number and percentage of genes with H3K56 acetylation that are also
bound by a particular transcription
E2F4~ 5340 4645 87.0% 45.5% 3444 73.9%
boundI
HSF-1- 174 157 90.2% 1.5% 93 68.9%
bound
C/EBPU- 5818 4290 73.7% 42.0% 2108 30.7%
bound
A: Total # of bound genes
B: # of bound genes with H3K56 acetylation
C: % of bound genes with H3K56 acetylation
D: % of all acetylated genes that are bound
E: # of peaks with neighboring* H3K56 acetylation
F: % of peaks with neighboring* H3K56 acetylation
*neighboring H3K56 acetylation means H3K56 acetylation occurs within 300 bases of
the particular transcription factor bound site identified by ChIP-Seq experiments.
Table 2-5 List of genes that have H3K56 acetylation and also bound by at least one
transcription factor
Table 2-6 Primer sequences used in this study
Both tables are not included due to space constraints. They can be found at
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjoumal.pone.0019778
Table 2-7 Gene sets that show a positive association with the ranked H3K56
acetylated genes
Gene Set N NES FWER p-value
Cell Communication 28 2.18 0.001
Focal Adhesion 109 2.05 0.011
Adipocytokine Signaling
Pathway 47 2.01 0.018
Type 2 Diabetes Mellitus 20 1.95 0.03
Melanoma 38 1.93 0.04
Bladder Cancer 29 1.92 0.043
N: number of genes in set. NES: normalized enrichment statistics.
Only results with a family-wise error rate (FWER) p-value <0.05 are shown
Table 2-8 Gene ontology (GO) categories associated with the bound/enriched genes
for each ChIP-Seq experiment
Biological Process (C/EBPa) All Found Expected p-value
Lipid, fatty acid and steroid metabolism 717 247 187.8 4.26E-04
Amino acid metabolism 209 81 54.74 1.53E-02
Other metabolism 537 178 140.65 3.56E-02
Biological Process (H3K56ac) Alil Found Epected p-value
Nucleoside, nucleotide and nucleic acid
metabolism 2894 1925 1603.48 1.49E-16
Protein metabolism and modification 2518 1636 1395.15 1.47E-10
Protein biosynthesis 309 268 171.21 4.40E-10
Intracellular protein traffic 906 642 501.99 1.18E-08
Protein modification 1089 712 603.38 6.65E-04
DNA metabolism 297 224 164.56 7.52E-04
Cell cycle 866 569 479.82 7.99E-04
Pre-mRNA processing 252 193 139.63 1.37E-03
mRNA splicing 184 146 101.95 4.26E-03
mRNA transcription 1694 1055 938.59 6.43E-03
Protein folding 144 116 79.79 1.14E-02
General vesicle transport 249 183 137.96 1.88E-02
Other metabolism 537 351 297.54 3.61E-02
Biological Process (E2F4) All Found Expected p-value
Nucleoside, nucleotide and nucleic acid
metabolism 2894 1136 835.89 1.79E-26
Cell cycle 866 389 250.13 1.11E-15
DNA metabolism 297 170 85.78 5.10E-14
Chromatin packaging and remodeling 193 111 55.75 4.95E-09
Pre-mRNA processing 252 131 72.79 5.54E-08
mRNA splicing 184 103 53.15 1.38E-07
DNA replication 108 68 31.19 1.03E-06
DNA repair 158 91 45.64 3.51E-07
Mitosis 306 137 88.38 1.14E-04
Protein biosynthesis 309 137 89.25 1.88E-04
Nuclear transport 81 46 23.4 3.23E-03
Cell cycle control 397 161 114.67 2.98E-03
Intracellular protein traffic 906 316 261.69 1.37E-02
DNA recombination 38 25 10.98 3.74E-02
Protein metabolism and modification 2518 803 727.29 4.44E-02
Biological Process (HSF-1) All Found Expected p-value
Protein folding 144 21 1.32 8.39E-17
Protein metabolism and modification 2518 54 23.13 2.19E-08
Protein complex assembly 65 8 0.6 2.93E-05
Stress response 191 11 1.75 2.77E-04
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3. Comprehensive analysis of
four in vitro insulin resistance
models and their physiological
relevance to adipose insulin
resistance resulting from diet-
induced obesity
3.1 Overview
Diet-induced obesity predisposes individuals to insulin resistance, and adipose tissue has
a major role in the etiology of disease. Adipose insulin resistance can be induced in
cultured adipocytes by a variety of treatments, but it is unknown what aspects of in vivo
adipose insulin resistance are captured by the different in vitro models. Here, we use
global RNA-sequencing (RNA-Seq) to investigate the gene expression changes of four
different in vitro insulin resistance models induced by treatments with TNFa, hypoxia,
dexamethasone, and high insulin. We analyzed these changes in parallel with those from
three independent microarray studies of white adipose tissue from diet-induced obese
(DIO) mice, examining the transcriptional effects on a genome-wide level and with a
focus on a set of 1,319 adipogenesis-related genes. We observed that while no in vitro
model could faithfully mimic all the transcriptional changes occurring in DIO mouse
adipose tissue, both TNFa and hypoxia treatments capture the downregulation of various
metabolic pathways, such as glucose, lipid, and branched-chain amino acid metabolic
pathways. Using genome-wide DNase I hypersensitivity cum sequencing analysis (DHS-
Seq), we further examined the transcriptional regulation of TNFa-induced insulin
resistance. We discovered that, in addition to NF-KB, C/EBPs is also likely to mediate
the gene induction upon TNFa treatment. We conclude that different in vitro models
capture different features of DIO adipose insulin resistance.
3.2 Introduction
Obesity has become a global epidemic as a result of the modem sedentary lifestyle and
the consumption of a high-calorie high-fat diet. Obesity predisposes individuals to
insulin resistance, a condition in which there is a reduced ability of a cell to respond to
the physiological level of insulin. This condition is a key component and risk factor of
many metabolic diseases (e.g., type 2 diabetes, hypertension, atherosclerosis, and
cardiovascular diseases) and cancer (Reaven 2005). Given its increasing prevalence and
disease association, there is considerable need and urgency to better understand insulin
resistance.
The 3T3-L1 cell line (Green and Meuth 1974) has been widely used to study
insulin resistance in adipocytes (Knutson and Balba 1997). Many agents can induce
insulin resistance in differentiated 3T3-L1; these include TNFa (Ruan, Hacohen et al.
2002), IL-1(Jager, Gr6meaux et al. 2007), IL-6 (Rotter, Nagaev et al. 2003), free fatty
acids (Nguyen, Satoh et al. 2005), dexamethasone (Sakoda, Ogihara et al. 2000), high
insulin (Thomson, Williams et al. 1997), glucosamine (Nelson, Robinson et al. 2000),
growth hormone (Smith, Elmendorf et al. 1997), and hypoxia (Regazzetti, Peraldi et al.
2009), etc. These agents are diverse in nature, and they presumably induce insulin
resistance through both shared and distinct mechanisms. It is unclear what features of in
vivo adipose insulin resistance are captured by each of the different in vitro models.
In order to better understand these widely used models of insulin resistance, we
have examined the changes in transcription and transcriptional regulation induced by
TNFa, hypoxia, dexamethasone, and high insulin in differentiated 3T3-L1 cells. TNFa is
a proinflammatory cytokine. It is secreted both by adipocytes and the resident
macrophages in adipose tissue. Since the discovery of its role in obesity-linked insulin
resistance (Hotamisligil, Shargill et al. 1993), it has been widely used to induce insulin
resistance in cultured cells. A more recently discovered way to induce insulin resistance
is hypoxia treatment. It has been shown that obese adipose tissue is hypoxic, and this
could lead to dysregulation of adipokine production (Hosogai, Fukuhara et al. 2007) and
insulin signaling (Regazzetti, Peraldi et al. 2009). Both TNFa and hypoxia have been
linked to inflammatory responses. Interestingly, dexamethasone, a synthetic
glucocorticoid frequently prescribed as an anti-inflammatory agent and
immunosuppressant, can also induce insulin resistance. Excessive use of dexamethasone
would result in Cushing's syndrome, characterized by central obesity, insulin resistance
and other metabolic abnormalities (Andrews and Walker 1999). Elevated endogenous
glucocorticoid (e.g., the hormone cortisol in humans and corticosterone in rodents) could
also lead to visceral obesity and aggravate high-fat diet-induced insulin resistance
(Masuzaki, Paterson et al. 2001; Wang 2005). Lastly, the supra-level of the hormone
insulin itself could also induce insulin resistance; both receptor and post-receptor defects
have been demonstrated (Martin, Desai et al. 1983). As a hallmark of insulin resistance,
hyperinsulinemia is postulated to be both the result and the driver of insulin resistance
(Shanik, Xu et al. 2008).
To understand the relationship of these models to each other and to the in vivo
setting, we have made use of high-throughput RNA-sequencing (RNA-Seq) technology
(Trapnell, Williams et al. 2010) and analyzed the in vitro data in parallel with adipose
tissue transcriptome data from three independent diet-induced obesity (DIO) mouse
models. We find that the models show diverse transcriptional responses, each of which
captures a different aspect of the in vivo data. The TNFa and hypoxia models capture the
downregulation of many glucose, lipid and amino acid metabolic pathways observed in
DIO mouse adipose tissue that are not detected in the high insulin and dexamethasone
models. Conversely, the upregulation of the inflammatory responses in DIO adipose
tissue is mainly captured by the TNFa model, and the upregulation of cell cycle
responses is captured by the high insulin, and to a lesser extent, the hypoxia model. We
further explored the differences in transcriptional regulation among the in vitro models
using DNase I hypersensitivity followed by massively parallel sequencing (DHS-Seq).
We observe many condition-specific changes in regulatory sites. Analysis of DHS-Seq
data from TNFa-induced insulin resistance revealed that in addition to NF-KB, C/EBPP is
a potential regulator mediating the gene induction occurring in TNFa-induced insulin
resistance. In addition, we find that loss of PPARy binding is likely to mediate many of
the gene repression changes upon TNFa treatment.
3.3 Additional background information
In this section, we provide additional description of the four in vitro insulin resistance
models. We focus on discussing the physiological relevance of the different models and
the current understanding of their mechanisms. The discussion below illustrates the
diverse origins of insulin resistance. The complexity of insulin resistance prompts us to
focus on one particular type of insulin resistance: insulin resistance caused by diet-
induced obesity. Our attempt is to identify the features of the different in vitro models
and relate them to actual in vivo transcriptome changes.
3.3.1 TNFa-induced insulin resistance
TNFa is a proinflammatory cytokine with a wide range of anti-tumor and immune
functions. Elevated TNFa level has been implicated in a wide range of diseases
including endotoxin lethality, rheumatoid arthritis, Crohn's disease, and tumor-induced
cachexia, etc. The role of TNFa in insulin resistance was discovered in 1993 when both
TNFa mRNA and protein expression was found to be elevated in various rodent models
of obesity and diabetes (Hotamisligil, Shargill et al. 1993).
TNFa affects insulin signaling by a variety of different mechanisms (David E
2000; Borst 2004). At the phosphorylation signaling level, TNFcL impairs tyrosine
phosphorylation of key signaling molecules, such as the insulin receptor and insulin
receptor substrate, by inducing serine phosphorylation and activating various protein
tyrosine phosphatases. At the transcription level, TNFa upregulates the expression of
many inflammatory molecules and downregulates many adipocytes important genes,
mainly by the transcription factor NF-icB (Ruan, Hacohen et al. 2002). TNFa
antagonizes the action of PPARy, the master regulator of adipogenesis and adipocyte
functions (Ye 2008). Furthermore, it enhances lipolysis, leading to an increase in
circulating free fatty acids. These free fatty acids may eventually accumulate in other
metabolic tissues, leading to lipotoxicity. TNFa treatment is the most commonly-used
method to induce insulin resistance; however, it is unknown how well TNFa treatment
actually mimics the in vivo transcriptome changes during diet-induced obesity.
3.3.2 Hypoxia-induced insulin resistance
While TNFa treatment represents one of the most well-established methods to induce
insulin resistance, hypoxia treatment is one of the newest methods. Obesity is
accompanied by both adipocyte hyperplasia (increase in cell number) and hypertrophy
(increase in cell size) (Jo, Gavrilova et al. 2009). Both processes lead to a massive
expansion of the volume of adipose tissue, which leads to local adipose hypoperfusion
and hypoxia. The hypoxic environment induces drastic changes in adipocyte energy
metabolism. In response to hypoxia, pyruvate dehydrogenase kinase (PDK) is markedly
upregulated. This shunts acetyl-CoA away from mitochondrial oxidation by converting
pyruvate to lactate. There is also marked upregulation of Glut1, which promotes insulin-
independent uptake of glucose. How these processes alter insulin sensitivity is largely
unknown.
Studies using both animal and cell culture models have provided strong support
for the role of hypoxia in insulin resistance. Hypoxic adipose tissue from obese mice has
an altered adipokine secretion profile: there is increased expression of leptin,
plasminogen activator inhibitor I (PAI-1), MMP-2 and adrenomedullin (ADM) and a
decreased expression of adiponectin (Hosogai, Fukuhara et al. 2007). At the signaling
level, hypoxic 3T3-L1 adipocytes have impaired tyrosine phosphorylation of insulin
receptor, protein kinase B and AS 160; their insulin-mediated glucose transport is also
compromised (Regazzetti, Peraldi et al. 2009). The reduction of adipose tissue
oxygenation is also demonstrated in obese humans, and this is associated with adipose
tissue inflammation (Pasarica, Sereda et al. 2009). Given the physiological relevance of
hypoxia in adipose insulin resistance, it is possible that hypoxia treatment in 3T3-L1
captures a lot of key features of obesity-induced insulin resistance.
3.3.3 Dexamethasone-induced insulin resistance
Dexamethasone is a synthetic glucocorticoid widely prescribed as an anti-inflammatory
and immunosuppressive agent for treating rheumatoid arthritis, bronchial asthma, allergy,
hematological disorders, and various renal, intestinal, liver, eye and skin diseases.
Endogenous glucocorticoid consists of a group of related steroid hormones released from
the cortex of the adrenal gland. In humans, the main endogenous glucocorticoid is
cortisol (corticosterone in mice). Active cortisol is converted from its inactive form
cortisone by 11[ hydroxysteroid dehydrogenase (11-HSD). Both exogenous and
endogenous glucocorticoids activate the glucocorticoid receptor (GR), a nuclear
transcription factor that mediates its action by binding to genomic cis-regulatory regions
to affect transcription.
Both excessive exogenous and endogenous glucocorticoids could lead to insulin
resistance. Chronic administration of dexamethasone is associated with Cushing's
syndrome, which is characterized by central obesity and insulin resistance.
Glucocorticoid-mediated insulin resistance extends beyond the side effects of
dexamethasone treatment: transgenic mice overexpressing 11p HSD-1 have increased
expression of corticosterone and suffer from diabetes, hyperlipidemia, and hyperphagia
(Masuzaki, Paterson et al. 2001). Conversely, I 1$ HSD-1 knock-out mice are protected
from hyperglycemia provoked by obesity or stress, likely as a result of the blunted
glucocorticoid actions (Kotelevtsev, Holmes et al. 1997).
Various mechanisms have been proposed to explain the effects of glucocorticoid-
induced insulin resistance. Using a peptide kinase array, a recent study suggests that
dexamethasone acts by a GR-dependent but transcription-independent inhibition of
insulin signal transduction (Lowenberg, Tuynman et al. 2006). Conversely, an earlier
study shows that dexamethasone causes insulin resistance in 3T3-L1 by inhibiting
glucose transport rather than by altering the insulin signaling cascade (Sakoda, Ogihara et
al. 2000). In search for a common mechanism of TNFa- and dexamethasone-induced
insulin resistance, Houstis et al reported that while these two agents have very few
common transcriptional targets, they both act by inducing genes related to reactive
oxygen species (Houstis, Rosen et al. 2006). However, no prior studies have compared if
glucocorticoid-induced insulin resistance resembles in vivo adipose insulin resistance
caused by diet-induced obesity.
3.3.4 High insulin-induced insulin resistance
Hyperinsulinemia, a defining feature of insulin resistance, may be the most physiological
relevant and prevalent condition associated with insulin resistance. It is a compensatory
mechanism mediated by the pancreatic beta cells to prevent the development of frank
diabetes in face of insulin resistance. However, this "philanthropic effect on the part of
the pancreatic beta cells" could be "a mixed blessing" (Reaven 2004), as
hyperinsulinemia predisposes individuals to the same cluster of metabolic abnormalities
as insulin resistance. Since insulin resistance is, by definition, tethered to
hyperinsulinemia, it is almost impossible to tease apart whether the metabolic
abnormalities are due to insulin resistance or hyperinsulinemia (or both).
Hyperinsulinemia is proposed to be both the cause and the consequence of insulin
resistance (Shanik, Xu et al. 2008). While hyperinsulinemia and insulin resistance is a
chicken and egg situation, it is likely that hyperinsulinemia can aggravate or perpetuate
the insulin resistant state. Hyperinsulinemia has been used to model insulin resistance in
vitro. Besides inducing insulin receptor desensitization and diminishing the insulin
phosphorylation cascade, the genomic effects of chronic insulin treatment may explain
some of the consequences of hyperinsulinemia. A study in 3T3-L1 identified 61 insulin
sensitive genes that continue to remain insulin sensitive after cells being rendered insulin
resistant (Sartipy and Loskutoff 2003). The authors proposed that signaling pathways
remain insulin-sensitive in insulin-resistant adipocytes may promote abnormal gene
expression. It has also been shown that in a model of chronic hyperinsulinemia,
adipocytes develop a state of selective insulin resistance whereby some signaling
pathways are impaired while others are largely preserved (Gonzalez, Flier et al. 2011).
This may lead to an uncoupling of the various metabolic actions of insulin, contributing
to the pathologies associated with obesity and type 2 diabetes. Given that
hyperinsulinemia is an obligatory response following insulin resistance, it is interesting to
see if the transcriptome changes caused by hyperinsulinemia are similar to those by
adipose insulin resistance.
3.4 Results
3.4.1 Setting up four diverse in vitro insulin resistance models in 3T3-
L1 cell line
We set up four diverse insulin resistance models in the cell line 3T3-L1: cells were
differentiated to mature adipocytes using the standard differentiation protocol, and then
rendered insulin resistant by four different treatments: TNFa, hypoxia, dexamethasone,
and high insulin (see Methods). All four models exhibited compromised insulin
responses: there were significant decreases in insulin-stimulated phosphorylation of Akt
at serine 473 (Figure 3-1A) and 2-deoxyglucose uptake (Figure 3-1B). Interestingly, the
level of reduction of the insulin-mediated responses was different for the four models.
This phenotypic heterogeneity is also observed for non-insulin-mediated processes: basal
glucose uptake was markedly elevated in both the TNFa and hypoxia models (Figure 3-
1B). These diverse phenotypes illustrate that among the four in vitro insulin resistance
models, both insulin-dependent and independent processes are altered differently. The
heterogeneity of the four models is also apparent on the transcriptional level when we
analyzed gene expression changes of five adipocyte marker genes by qPCR (Figure 3-1C).
For example, the expression of Pparg, the master regulator of adipogenesis and adipocyte
function, decreases in the TNFL model but increases in all other models; the insulin-
sensitizing adipokine adiponectin (Adipoq), decreases in all models except the high
insulin model. The insulin-independent glucose transporter Glut1 shows more than four-
fold induction in the TNFa and hypoxia models (in good agreement with the basal
glucose uptake data). The above examples suggest that the transcriptome shifts under the
four insulin resistance models are likely to be diverse and distinct.
In order to obtain a genome-wide picture of the transcriptional outcomes of the
four models, we carried out high-throughput RNA-Seq on biological triplicates of each
model and the control model (untreated mature 3T3-L1 adipocytes). We quantified the
expression levels of all Refseq genes and performed differential gene expression analysis
using Cuffdiff (Trapnell, Williams et al. 2010) by comparing the gene expression of each
insulin resistance model with the control model (see Methods). While qPCR quantifies
the relative expression levels of genes with respect to a housekeeping gene, RNA-Seq
measures the absolute expression levels of transcripts in FPKM (fragments per kilobase
of transcript per million fragments mapped). The absolute expression of the above five
adipocyte marker genes measured by RNA-Seq (Figure3- ID) closely resembles their
relative expression measured by qPCR (Figure 3-1C). There is a high correlation
between the qPCR and RNA-Seq results (r = 0.92, Figure 3-1E), suggesting that the gene
expression changes measured by RNA-Seq are similar to those measured by qPCR.
3.4.2 Diverse transcriptional changes associated with models of insulin
resistance
The diverse effects of each method of inducing insulin resistance can be seen by
analyzing glycolysis and triglyceride synthesis and degradation, key pathways of adipose
metabolism. The enzymes that catalyze the irreversible steps of glycolysis, including
hexokinase (Hkland Hk2), phosphofructokinase (Pfkl and Pfkp), and pyruvate kinase
(Pkm2), are upregulated after the hypoxia, high insulin and TNFa treatments but not the
dexamethasone treatment (Figure 3-2). Regarding the triglyceride synthesis and
degradation pathway (Figure 3-3), diacylglycerol O-aceyltransferases (Dgatl and Dgat2),
which catalyze the reaction in which diacylglycerol is covalently joined to long chain
fatty acyl-CoAs, are repressed in the hypoxia and TNFa models but not the high insulin
model. Hormone sensitive lipase (Lipe), which hydrolyses stored triglyceride to free
fatty acid, is downregulated after TNFa treatment as previously reported (Ruan, Hacohen
et al. 2002); it is also repressed in the hypoxia model but not in the high insulin and
dexamethasone models.
To explore the diverse gene expression changes at a genome-wide level, we
performed gene ontology (GO) analysis of the differentially expressed genes (log 2 fold
change > 0.58 or < -0.58 and qval <0.05) of each in vitro model compared to the control
model. The TNFa model changes the expression of the largest number of genes among
the four models (Tables 3-1 and 3-2). In agreement with the role of TNFa as an
inflammatory cytokine, TNFa-induced genes are most enriched in immune response, and
TNFa-repressed genes are most enriched in fatty acid metabolic process. Conversely,
dexamethasone treatment changes the expression of the least number of genes (Tables 3-
1 and 3-2): dexamethasone-induced genes are enriched in response to peptide hormone,
and dexamethasone-repressed genes are not significantly enriched in any GO categories.
For the high insulin model, genes that are upregulated by high insulin are enriched in
sterol and lipid biosynthetic processes, while genes that are downregulated by high
insulin are mainly related to transcription and translation. Lastly, for the hypoxia model,
the upregulated genes are enriched in transcription and glycolysis, and the downregulated
genes are enriched in oxidation reduction and fatty acid metabolic process (Tables 3-1
and 3-2).
3.4.3 Anti-adipogenesis transcriptome shift of DIO mouse adipose
tissue captured mainly by the TNFa and hypoxia models
To understand how the in vitro expression changes relate to mouse insulin resistance
models, we analyzed three independent microarray data sets comparing the gene
expression of adipose tissue from DIO mice and normal chow diet-fed mice (Qi, Saberi et
al. 2009; Fitzgibbons, Kogan et al. 2011; Fujisaka, Usui et al. 2011). These three DIO
mouse expression studies used different high-fat diet formulations (30% to 60% of
calorie from fat) and different durations of high-fat feeding (12 weeks to 24 weeks)
(Table 3-3). Nonetheless, the Pearson correlation coefficients of the genome-wide
expression fold changes (expression of DIO mouse versus control mouse) among the
three data sets range from 0.53 to 0.69, indicating that the expression profiles of these
three DIO mouse data sets are similar.
As the in vivo data are likely to contain contributions from multiple cell types, we
chose to focus our analysis on a set of genes that are most relevant to adipocytes. To this
end, we first identified a set of adipogenesis-related genes that shows consistent
expression changes between preadipocytes and adipocytes from three independent data
sets: two are microarray data sets on the 3T3-L1 adipogenesis process (Schupp,
Cristancho et al. 2009; Mikkelsen, Xu et al. 2010) , and one is a RNA-Seq data set on
mouse primary preadipocytes differentiated in vitro (Sun, submitted) (Table 3-4). We
identified a set of 1,319 concordantly differentially expressed (fold change > 2 or < 0.5,
qval < 0.05) adipogenesis-related genes, which consists of 640 consistently upregulated
and 679 downregulated genes during adipogenesis. We call them adipogenesis-induced
and adipogenesis-repressed genes, respectively, because they show consistent
transcriptional changes during adipogenesis in both 3T3-L1 and primary adipocytes.
We first performed hierarchical clustering analysis of this set of 1,319
adipogenesis-related genes of the three adipogenesis data sets. The resulting dendrogram
(Figure 3-4A) indicates that the two 3T3-L1 data sets (Adipogenesis1 and Adipogenesis2)
are more similar to each other than to the primary adipocyte data set (Adipogenesis 3).
However, the distance between the Adipogenesis1-Adipogenesis2 cluster and the
Adipogenesis3 data set is shorter than the distance between any two in vitro or in vivo
insulin resistance models (see below); this suggests that the 3T3-L1 cell line model can
reasonably mimic the transcriptome changes of this set of 1,319 adipogenesis-related
genes in primary adipocytes.
Hierarchical clustering analysis of the seven insulin resistance models (four in
vitro models and three DIO mouse models) reveals a striking anti-adipogenesis
transcriptome shift of the three DIO mouse models (Figure 3-4A). Many adipogenesis-
induced genes are downregulated in the DIO mouse models; conversely, many
adipogenesis-repressed genes are upregulated. It is clear by visual inspection that both
the TNFa and hypoxia models also exhibit this anti-adipogenesis transcriptome shift.
Dendrograms from hierarchical clustering confirm that both the TNFa and hypoxia
models capture the anti-adipogenesis transcriptome shift more than the high insulin and
dexamethasone models (Figures 3-4A and 3-5).
We quantified the percentage of genes that undergo the anti-adipogenesis
transcriptome shift (adipogenesis-induced genes are repressed and adipogenesis-
repressed genes are induced by more than 1.5 fold) in each model (Figure 3-4B).
Approximately half of the adipogenesis-related genes undergo the anti-adipogenesis
transcriptome shift in vivo: of the 640 adipogenesis-induced genes, 352 (55%) are
repressed by more than 1.5 fold in at least one of the three DIO mouse models. These
adipogenesis-induced-DIO-repressed genes are highly enriched in oxidation reduction (p:
6.3E-17: 53 genes), fat cell differentiation (p: 1.2E-8: l4genes) and various metabolic
processes (e.g., cofactor metabolic process, fatty acid metabolic process, carboxylic acid
catabolic process, branched-chain fatty acid metabolic process, and glucose metabolic
process) (p < 1E-4 for all the above processes). Conversely, 298 of the 679 (44%)
adipogenesis-repressed genes are induced by more than 1.5 fold in at least one of the
three DIO mouse models. These adipogenesis-repressed-DIO-induced genes are enriched
in cell-cycle related categories such as M-phase (p: 1.9E-28; 47 genes) and DNA
replication (p: 5.3E-13; 24 genes), and inflammation-related categories such as cellular
response to stress (p: 5.8E-3; 20 genes) and chemotaxis (p: 0.03; 9 genes). Among the
three DIO mouse models, WATI has the highest percentage of adipogenesis-induced
genes that are downregulated; it also has the highest percentage of adipogenesis-
repressed genes that are upregulated.
Among the four in vitro models, the TNFa model has the highest percentage of
genes that undergo the anti-adipogenesis transcriptome shift. The hypoxia model also
represses a significant percentage of adipogenesis-induced genes and induces a
significant percentage of adipogenesis-repressed genes. Interestingly, while the high
insulin model upregulates a significant percentage of both adipogenesis-induced and -
repressed genes, the dexamethasone model represses a significant percentage of both
adipogenesis-induced and -repressed genes (Figure 3-4B).
To identify which features of DIO adipose insulin resistance are captured by each
in vitro model, we analyzed the fraction of genes that undergo the anti-adipogenesis
transcriptome shift in vivo and show concordant changes in vitro (Figure 3-4C). Gene
ontology analysis identifies features that the different in vitro models capture solely or
jointly (Table 3-5). For example, the adipogenesis-induced-DIO-repressed genes that are
repressed by TNFa, hypoxia, and dexamethasone are enriched in fat cell differentiation,
oxidation reduction (redox), and lipid catabolism, respectively (Table 3-5). Interestingly,
the 104 genes that are only repressed in the TNFa model are also most enriched in the
process of fat cell differentiation (Table 3-5). Although there are 63 redox-related genes
that are repressed in both the TNFi and hypoxia models, there are 93 other redox-related
genes whose repression is not captured by any of the in vitro models (Table 3-5).
Regarding the adipogenesis-repressed-DIO-induced genes, those that are only
induced in the TNFa model are enriched in immune system process and chemotaxis
(Table 3-6). Interestingly, the 57 and 96 genes that are induced in the hypoxia and high
insulin models, respectively, are both enriched in M phase of cell cycle (Table 3-6).
There are 98 adipogenesis-repressed-DIO-induced genes that are not induced by the in
vitro models; they are enriched in DNA replication (Table 3-6). These model-specific
analyses show that the different in vitro models mimic different aspects of DIO adipose
insulin resistance, and there are close to 200 genes whose in vivo upregulation or
downregulation are not captured by any of the in vitro models (Tables 3-5 and 3-6).
We also carried out principal component analysis (PCA) of the 1,319
adipogenesis-related genes of the three mouse and four in vitro models. PCA is a
standard technique for reducing the dimensionality of data sets involving a large number
of measurements (e.g., RNA-Seq data sets measuring genome-wide expression changes
across multiple conditions) but at the same time retaining as much variability as possible.
The principal components identified by this method are combinations of genes that
represent the greatest source of variation in the expression data. The first principal
component (PC1) explains 25.1% of the variance of the expression changes among the
seven models. Projecting each data set along this axis reveals that the mouse models are
well separated from the in vitro models. Of the in vitro models, TNFa is the closest to
the mouse models (Figure 3-4D). To understand better what this principal component
represents, we examined the 30 genes with the most positive or negative loadings. Genes
associated with the most positive loadings are enriched in inflammatory response (p: 0.04;
5 genes: Cxcl5, Cd44, Ccl5, Ccl2, and Ccl7) and chemotaxis (p: 0.008; 5 genes: Ccl9,
Cxcl5, Ccl5, Ccl2, and Ccl7). Conversely, the 30 genes that contribute to the loadings
with the most negative values are enriched in oxidation reduction (p: 0.05; 8 genes: Egln2,
Prodh, Cyp2f2, Fmol, Hsdllbl, Phyhdl, Aldh1a7, and Ptgsl) and fat cell differentiation
(p: 0.04; 4 genes: Retn, Selenbpl, Slc2a4, and Arl4a). Genes contributing to the 30 most
positive loadings to the second principal component (PC2) are enriched in M phase (p:
1.9E-8; 10 genes: Ccnbl, Fam83d, Ccnb2, Kifl1, Mki67, Plkl, Nuf2, Bub], Ube2c, and
Ccna2), and genes that contribute to the 30 most negative loadings do not show any
particular enrichment for functional categories. Along this axis, we find that hypoxia is
extremely similar to the in vivo models. Interestingly, we find that TNFa and
dexamethasone are extremely similar to each other along this dimension (Figure 3-4D)..
We repeated the principal component analysis at a genome-wide level by using all
13,043 genes with FPKM > 0.1. The first principal component from the genome-wide
PCA also separates the mouse models from the cell line models, and once again the
TNFca model is closest to the mouse models (Figure 3-4D). Interestingly, although we
include 10 times more genes in the genome-wide PCA, genes corresponding to the most
positive loadings are associated with the same categories as we observed when analyzing
only the adipogenesis-related genes: fat cell differentiation (p: 2E-4: 10 genes out of the
top 300) and oxidation reduction (p: 3.8E-4: 31 genes out of the top 300), and genes
corresponding to the most negative loadings are associated with immune system process
(p: 0.02; 29 out of top 300 genes). PC2 identified using the full set of 13,043 genes is
associated with M phase (p: 7.3E-8; 23 genes out of the 300 genes with the most positive
loadings), and genes corresponding to the 300 most negative loadings do not show any
particular enrichment for functional categories. Along this axis, TNFa and hypoxia are
extremely similar to the in vivo data (Figure 3-4D)..
3.4.4 Systemic transcriptome changes in adipose insulin resistance
revealed by pathway analysis
In order to systematically analyze pathway changes that occurred during adipose insulin
resistance, we also adopted a pathway-orientated method. We analyzed each condition
using gene set enrichment analysis (GSEA) (Subramanian, Tamayo et al. 2005) of the
1,319 adipogenesis-related genes. Plotting the enrichment scores for each condition in a
heatmap reveals pathways that are upregulated or downregulated in the mouse models
and the different in vitro models (Figure 3-6A). Two distinct features can be identified
from the heatmap: a group of consistently downregulated pathways (Figure 3-6B) and a
group of consistently upregulated pathways (Figure 3-6C) in the DIO mouse models.
The downregulated pathways include various glucose and lipid metabolic pathways (e.g.,
glucose metabolism, PPAR signaling, pyruvate metabolism, peroxisome, metabolism of
lipids and lipoproteins, and insulin signaling pathways). Interestingly, the downregulated
pathways also include pathways related to branched-chain amino acid catabolism (KEGG
valine, leucine, and isoleucine degradation pathway and Reactome branched-chain amino
acid catabolism pathway). It is noticeable that while both the TNFa and hypoxia models
capture the direction of change (i.e. downregulation) of these pathways, the extent of
downregulation in the in vitro models is not as significant as the DIO mouse models.
Figure 3-7 illustrates the expression changes of genes of the KEGG valine, leucine, and
isoleucine degradation pathway. It documents the downregulation of many key enzymes
(e.g., branched-chain amino acid transaminase 2 (Bcat2), dihydrolipoamide branched
chain transacylase E2 (Dbt), branched-chain keto acid dehydrogenase El, alpha
polypeptide (Bckdha)) involved in branched-chain amino acid metabolism in the TNFa
and hypoxia, but not in the dexamethasone and high insulin models. Similarly, the
dexamethasone and high insulin models also do not capture the in vivo downregulation of
the various lipid and glucose metabolic pathways (Figure 3-6B). In fact, many of these
pathways are upregulated rather than downregulated in the high insulin model, and they
do not show any significant changes in the dexamethasone model. Pathways that are
concordantly upregulated in vivo are mainly related to the cell cycle and mitosis
processes. Among the four in vitro models, the hypoxia and high insulin models capture
the upregulation of these pathways; with the high insulin model more closely captures the
magnitude of upregulation than the hypoxia model (Figure 3-6C).
We repeated the above GSEA pathway analysis using genome-wide expression
data rather than the smaller number of genes upregulated or downregulated during
adipogenesis (Figure 3-6D). Although the number of pathway analyzed increases from
82 to 479, the most significant in vivo downregulated pathways are still the various
metabolic pathways. Detailed illustrations of the gene expression changes across the in
vivo and in vitro models of the insulin signaling pathway, the triglyceride synthesis
pathway, the tricarboxylic acid cycle, the electron transport chain, and the glycolysis
pathway are shown in Figures 3-8 to 3-12. As before, the TNFa and hypoxia models, but
not the high insulin or dexamethasone models can capture the downregulation (Figure 3-
6E). Including this larger set of genes reveals some additional in vivo downregulated
pathways such as KEGG beta alanine metabolism and KEGG butanoate metabolism
pathways that did not reach statistical significance in the analysis of the 1,319
adipogenesis-related genes. Furthermore, several cytochrome detoxification-related
pathways (Reactome Phase II conjugation pathway, KEGG drug metabolism cytochrome
P450 pathway, and KEGG metabolism of xenobiotics by cytochrome P450 pathway) are
also found to be downregulated in vivo, which is mainly mimicked by the TNFa and
hypoxia models (Figure 3-6E). Conversely, the most significant upregulated pathways in
vivo based on genome-wide GSEA are mainly related to immune responses. We found
that the TNFa model, and to a lesser extent, the hypoxia model and the high insulin
models, capture the upregulation of these pathways (Figure 3-6F).
3.4.5 Identifying key regulators of TNF(a-induced insulin resistance
The diverse transcriptional patterns of the in vitro models suggest that different
transcriptional regulators are active under these conditions. In order to identify these
transcription factors, we used an unbiased strategy based on DNase I hypersensitivity
(DHS) experiment followed by high-throughput sequencing (DHS-Seq). This technique
has been used to identify regulatory regions where transcription factors are bound
(Hesselberth, Chen et al. 2009; Siersbaek, Nielsen et al. 2011), and computational
analysis of the sequences of hypersensitive regions can reveal the identity of the bound
transcription factors (Eguchi, Yan et al. 2008; Ling, Sugathan et al. 2010).
We digested intact nuclei from untreated and treated 3T3-Ll with the
endonuclease DNase I. Two-hit fragments released by DNase I treatment were isolated,
purified, sequenced, and aligned to the reference mouse genome mm9 (see Methods).
Pparg, which is expressed under the control and insulin resistant conditions (Figures 3-
1C and 3-1D), shows sites of hypersensitivity under all these conditions, as expected
(Figure 3-13A). In particular, there are three DNase hypersensitive regions within 5kb of
the Pparg2 promoter. These regions overlap with DNase hypersensitive regions in Day 6
differentiated 3T3-L1 (Siersbaek, Nielsen et al. 2011) and mouse fat pad (Birney,
Stamatoyannopoulos et al. 2007), as well as PPARy bound regions identified by ChIP-
Seq (Mikkelsen, Xu et al. 2010) (Figure 3-13A). Figure 3-14 shows an example of a
region where there is an increase in DNase hypersensitivity after the TNFa, hypoxia and
dexamethasone treatments, but a decrease in DNase hypersensitivity after the high insulin
treatment.
To discover potential transcriptional regulators of the response to each treatment,
we performed motif analysis of sites that changed in hypersensitivity. We identified
regions of differential hypersensitivity using the MACS algorithm (Zhang, Liu et al. 2008)
(see Methods) and analyzed the sequences of these regions using the motif discovery
algorithm, THEME (MacIsaac, Gordon et al. 2006). As expected, hypersensitive sites
induced by TNFa treatment are most strongly enriched for the motifs of AP-1 and NF-rcB,
while those induced by dexamethasone treatment are most strongly enriched for the motif
of the glucocorticoid receptor (GR). The motif of the hypoxia-inducible factor (Hif),
along with AP-1-related motifs (Bach, Nrf2, and Creb), are detected in DNase
hypersensitive regions induced by hypoxia. The DNase hypersensitive regions induced
after high insulin treatment did not yield any DNA sequence motif with a cross validation
error < 0.4 (Table 3-7). Similarly, very few DNA sequence motifs in regions with
decreased DNase hypersensitive after the four different treatments have a cross validation
error < 0.4 (Table 3-8).
As the DHS-Seq data for TNFa-induced insulin resistance were of particularly
high quality, we examined these in the greatest detail. MACS analysis shows that there
are 1,821 regions that lose DNase hypersensitivity and 4,773 regions that gain DNase
hypersensitivity after TNFa treatment genome-wide, examples of which are shown in
Figure 3-13B. First, we asked whether genes near regions with altered DNase
hypersensitivity are more likely to be differentially expressed. Of the 293 genes that are
located within 10 kilobases (kb) of regions with decreased DNase hypersensitivity, 30%
of the genes (89 genes, examples: Cfd, ScdJ, and Adipoq, etc) are downregulated (p <
2.2E-16) and only 3.1% (9 genes) are upregulated (p =1). Conversely, of the 930 genes
that are located within 10kb of regions with increased DNase hypersensitivity, 34% of the
genes (319 genes, examples: Glut1, Lcn2, and 1115) are upregulated (p < 2.2E-16) and
only 4.7% (44 genes) are downregulated (p = 1) (Figure 3-13C). We repeated the same
analysis of genes located within 2kb of regions with altered DNase hypersensitivity, and
we found a similar relationship between changes in DNase hypersensitivity and changes
in gene expression (Figure 3-15). This suggests that genes located in regions with
increased DNase hypersensitivity are more likely to be upregulated, and genes located in
regions with decreased DNase hypersensitivity are more likely to be downregulated
(Figure 3-13C).
Regions that gain or lose DNase hypersensitivity, therefore, represent potential
sites where there is a gain or loss of regulator binding. Using THEME (MacIsaac,
Gordon et al. 2006), we found that the PPAR motif is the top motif in the regions that
lose DNase hypersensitivity in the proximity of the TNFa-repressed genes (Table 3-9).
In fact, we observed specific loss of hypersensitivity at sites previously shown to be
bound by PPARy (Mikkelsen, Xu et al. 2010). The average DNase hypersensitivity
profile around PPARy bound sites decreases in the TNFa-treated cells (p: 8.44E-10)
(Figure 3-13D). By contrast, DNase hypersensitivity did not change at E2F4 bound
regions (p = 0.49) (Figure 3-13D) (MacIsaac, Lo et al. 2010). Thus, it appears that
PPARy may be an important regulator of TNFa-repressed genes.
Regions with increased DNase hypersensitivity near the TNFa-induced genes
were associated with motifs for NF-rB, AP-1, C/EBP, CREB and Tead (Table S7). NF-
icB and the AP-1 are known mediators of TNFa-induced insulin resistance. We carried
out a p65 ChIP-Seq experiment on the TNFa-treated cells, and we found that close to 60%
of the high confident p65 bound sites (p < 1E- 10, 260 out of 437) overlap with the TNFa-
induced DNase hypersensitivity regions. Examples of p65 bound genes include Ccl2,
Ccl7, Saa3, Hp and Lcn2, etc, many of which are well-known targets of NF-cB. The
average DNase hypersensitivity profile around p65 bound sites increases in the TNFa-
treated cells (p: 1.3E-7) compared to the control (Figure 4D). It is noteworthy that the
C/EBP motif is highly enriched at p65-bound sites (Figure 4E and Table S8). This
observation suggests that one or more members of the C/EBP transcription factor family
are not only potential regulator of TNFa-induced insulin resistance, but use some of the
same regulatory sites as p65.
Regions with increased DNase hypersensitivity near the TNFa-induced genes
were associated with motifs for NF-cB, AP-1, C/EBP, CREB and Tead (Table 3-10).
NF-icB and the AP-1 are known mediators of TNFa-induced insulin resistance. We
carried out a p65 ChIP-Seq experiment on the TNFQ-treated cells, and we found that
close to 60% of the high confident p65 bound sites (p < 1E-10, 260 out of 437) overlap
with the TNFa-induced DNase hypersensitivity regions. Examples of p65 bound genes
include Ccl2, Ccl7, Saa3, Hp and Lcn2, etc, many of which are well-known targets of
NF-KB. The average DNase hypersensitivity profile around p65 bound sites increases in
the TNFa-treated cells (p: 1.3E-7) compared to the control (Figure 3-13D). It is
noteworthy that the C/EBP motif is highly enriched at p65-bound sites (Figure 3-13E and
Table 3-11). This observation suggests that one or more members of the C/EBP
transcription factor family are not only potential regulator of TNFa-induced insulin
resistance, but use some of the same regulatory sites as p65.
3.4.6 C/EBPp in TNFa-induced insulin resistance
Having shown that the C/EBP motif is enriched in regions with increased DNase
hypersensitivity near the TNFa-induced genes, we next asked which member(s) of the
C/EBP family could be associated with the increased DNase hypersensitivity and gene
induction. Our RNA-Seq data indicates that among the six C/EBP family members, only
Cebpb and Cebpd show increased expression after TNFa treatment (Figure 3-16A). We
focused our analysis on Cebpb, which is expressed at a higher level. We confirmed that
the mRNA expression of Cebpb is indeed increased after TNFa treatment using qPCR
(data not shown), and we further show that the protein expression of C/EBP$ also
increases after TNFa treatment (Figure 3-16B). In addition, we performed the same
analyses on white adipose tissue harvested from mice fed a high-fat diet and mice fed a
normal chow diet. While there is no difference in Cebpb mRNA expression between the
DIO and control mouse adipose tissue (Figure 3-16C), C/EBPp protein expression is
higher in the DIO mouse adipose tissue (Figure 3-16D).
To assess if C/EBPp binds to the regulatory regions of TNFa-induced genes, we
carried out C/EBPP ChIP experiments on selected loci with increased DNase
hypersensitivity near TNFa-induced genes. We observed a significant increase in
binding of C/EBPP in the TNFa-treated cells over control at the regulatory regions of
Lcn2, Socs3, Glut1, and 1115 but not at the control region (Alb) (Figure 3-16E).
3.5 Discussion
We have presented global transcriptome profiling of four diverse in vitro insulin
resistance models and compared them with three independent DIO mouse models. Our
results show that each model captures distinct aspects of the in vivo changes. One
previous study has examined TNFi- and dexamethasone-induced insulin resistance
(Houstis, Rosen et al. 2006) and identified the common pathways showing transcriptional
changes. By including hypoxia and high-insulin in our study and using next-generation
sequencing, we have provided a much more complete understanding of the mechanisms
of insulin resistance. We find specific pathways that are altered in vivo and are captured
by individual models and combinations of models, and we are able to identify several
transcriptional regulators that are likely to drive these changes.
It is not surprising that no single in vitro model captures all the features of DIO
adipose insulin resistance, which are complicated phenotypes depending on multiple
factors (e.g., mouse strain, high-fat diet formulation, and duration of high-fat feeding).
Nevertheless, TNFct and hypoxia models are able to recapitulate a wide range of the
transcriptional changes including many changes associated with metabolic pathways.
The impairment of metabolic pathways is not limited to the relatively well-studied
glucose and lipid metabolic pathways. For example, the cytochrome P450 metabolic
pathways are found to be downregulated in vivo and in the TNFa and hypoxia models.
White fat was suggested to have a prominent detoxification function from a recent
proteomics study (Forner, Kumar et al. 2009). Our analysis suggests that this function is
impaired in DIO mouse adipose tissue and also in the TNFa and hypoxia models.
Moreover, we also observed the downregulation of branched-chain amino acid catabolic
pathways in vivo and in the TNFa and hypoxia models, but not in the high insulin and
dexamethasone models. Levels of branched-chain amino acids (valine, leucine, and
isoleucine) are elevated in obese (Newgard, An et al. 2009) and diabetes-prone (Wang,
Larson et al. 2011) humans. In addition, oxidation enzymes for branched-chain amino
acids are found to be downregulated in adipose tissue of obese and insulin-resistant
humans (Pietilainen, Naukkarinen et al. 2008). Our study highlights the downregulation
of these pathways in DIO mice and shows that the TNFa and hypoxia models capture the
pathway downregulation.
Furthermore, our studies identify features that the four in vitro models uniquely or
jointly capture. For example, the TNF model captures the dedifferentiation-,
chemotaxis- and inflammation-related features that are observed in vivo. In particular,
we found that TNFa is the only model among the four that can mimic the upregulation of
genes related to chemotaxis. Indeed, three chemotaxis genes upregulated by TNFa (Cc2,
Ccl7, and Ccl9) are among the six chemotactic factors that are consistently upregulated in
adipose tissue, and predominantly adipocytes, of ob/ob and DIO mice (Jiao, Chen et al.
2009). The chemotactic nature of DIO adipocytes is suggested to contribute to
macrophage infiltration and the ensuing chronic inflammatory responses (Weisberg,
McCann et al. 2003). As for the inflammatory responses associated with insulin
resistance, TNFa is also largely able to replicate these. Conversely, hypoxia, high insulin
and dexamethasone are not good models to capture the inflammation-related aspect of
adipose insulin resistance. Given that dexamethasone is anti-inflammatory in nature, this
is not surprising. However, it is rather surprising that hypoxia could not model the DIO-
induced inflammatory responses well, because adipose hypoxia has been associated with
an increase in expression of many inflammatory genes and the activation of NF-cB and
TNFa (Ye, Gao et al. 2007). We are confident that our hypoxic treatment was working
since various hypoxia-responsive genes (e.g., Glut1, heme oxygenase 1 (Hmox1),
pyruvate dehydrogenase kinase 1(Pdkl) and vascular endothelial growth factor (Vegfia))
were markedly upregulated in the hypoxia-treated cells; however, we cannot rule out that
a longer duration of hypoxic treatment (> 24h) is required to trigger the inflammatory
responses in vitro.
While the TNFa model captures the various immune response-related features,
the high insulin model, and to a lesser extent, the hypoxia model, capture the
upregulation of the cell cycle process and mitosis. This is in agreement with a recent
study comparing gene expression of adipose tissue from insulin-resistant and insulin-
sensitive subjects with matched BMI (Elbein, Kern et al. 2011), in which many genes
related to cell cycle progress and cell adhesion were found to be differentially expressed.
In our analysis, dexamethasone appears to be the model that is the least relevant
to DIO adipose insulin resistance at the transcriptional level. However, we cannot
exclude the possibility that dexamethasone induces proteomic changes that are similar to
those in vivo. It is also plausible that the dexamethasone model is a better model for
capturing features of insulin resistance of a different origin, such as insulin resistance
associated with Cushing's syndrome.
It is important to note that we analyzed our four in vitro models in parallel with
data from DIO mouse whole adipose tissue but not isolated adipocytes. Adipose tissue is
a heterogeneous tissue comprising multiple cell types: these include mature adipocytes,
preadipocytes, resident immune cells and endothelial cells. Upon high-fat feeding, there
is massive infiltration of activated macrophages into white adipose tissue (Weisberg,
McCann et al. 2003). A recent study quantified that the stromal vascular fraction of
collagenase-digested adipose tissue from high fat diet-fed mice contains 31.7% of
CD1 1b+/CD1 1c+ macrophages versus 11.1% from normal diet-fed mice (Fitzgibbons,
Kogan et al. 2011). We avoided isolating adipocytes from adipose tissue because any
procedures used to extract adipocytes from adipose tissue would likely change the gene
expression of the adipocytes. It has previously been demonstrated that the standard
method to isolate primary adipocytes from mouse fat pads induces inflammatory
mediators and downregulates adipocyte genes (Ruan, Zarnowski et al. 2003). There is no
perfect experimental or computational method for determining the expression changes in
DIO that arise solely from adipocytes. However, by focusing our analysis on the 1,319
genes that change during adipogenesis, we are able to reduce the contribution from other
cell types.
By combining genome-wide RNA-Seq with DHS-Seq analysis, we explored in
detail transcription regulation of TNFx-induced insulin resistance. We identified that, in
addition to known regulators such as PPARy and NF-iB, C/EBPp is also a potential
mediator of TNFa-induced insulin resistance. It binds to a number of TNFa-induced
genes, potentially regulating their expression. Whole-body C/EBPp deletion has been
shown to protect against obesity and insulin resistance upon high-fat diet (Millward,
Heaney et al. 2007) and to reduce adiposity and hepatic steatosis in db/db mice
(Schroeder-Gloeckler, Rahman et al. 2007). C/EBP3 has been extensively studied in the
context of adipogenesis (Steger, Grant et al. 2010; Siersbaek, Nielsen et al. 2011);
however, its role in TNFa-induced insulin resistance has not been explored. We show
that C/EBPp protein expression increases upon TNFa treatment and high-fat diet feeding,
and it binds to the regulatory regions of several induced genes in TNFa-treated 3T3-Ll.
In conclusion, our study highlights the particular features that the four in vitro
models capture. This comprehensive and accurate description of the transcriptome
changes of the four 3T3-L1 insulin resistance models will be a rich resource for future
studies.
3.6 Materials and Methods
Cell culture and differentiation
3T3-L1 was grown and differentiated to mature adipocyte as described (MacIsaac, Lo et
al. 2010). In brief, 3T3-Ll cells (ATCC) were maintained in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% bovine serum (Invitrogen), 100
units/ml penicillin, and 100pg/ml streptomycin. Two days after confluence (Day 0), cells
were induced to differentiate with DMEM containing 10% fetal bovine serum (FBS) ,
1pM dexamethasone, 10 pg/ml insulin and 0.5mM 3-isobutyl-1-methyxanthine for 2
days. Cells were then incubated in DMEM containing 10% FBS and 10 pg/ml insulin for
2 more days. After Day 4, cells were maintained in DMEM containing 10% FBS, with
medium change every other day. Experiments were performed using Day 8 to Day12
mature adipocytes.
In-vitro cellular insulin resistance models
Before starting any insulin resistance-inducing treatment, cells were washed with PBS
and changed to serum-free, low-glucose (1g/L) DMEM with 0.5% BSA. For the TNFa
treatment, cells were treated with 2.5pM of TNFa (R & D Systems) for 24h, the time at
which expression changes of selected marker genes have reached a plateau (Figure 3-17).
For hypoxia treatments, cells were incubated in a 1% oxygen chamber (Powers, Millman
et al. 2010) for 24h. Two types of hormonal stress were used to induce insulin resistance:
dexamethasone treatment consisted of 24h incubation with 1pM dexamethasone (Sigma);
high insulin treatment consisted of 24h incubation of 100nM insulin (Sigma) in high
glucose (4.5g/L) medium.
Western blot analysis
3T3-L1 adipocytes were treated with the different insulin resistance-inducing agents for
24h, except in the case of high insulin where the medium was changed to a low-glucose
insulin-free medium during the last hour to recover from chronic insulin treatment. Cells
were then stimulated with 20nM of insulin for 10min. They were then lysed in RIPA
buffer with protease and phosphatase inhibitors. Proteins were extracted and quantified
using Bradford reagent. 30ug of soluble protein was boiled with sample loading buffer
for 10min and loaded onto a Criterion TGX precast gel (Bio-Rad) for sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins on the SDS-PAGE gel
were then immunoblotted onto nitrocellular membranes. Primary antibodies were then
used to probe for the protein of interest: pAkt (Cell Signaling 4051), C/EBPO (Santa Cruz
Biotechnology sc-150), and loading control Akt (Cell Signaling 9272). Membranes were
then washed and incubated with horseradish peroxidase-conjugated secondary antibody.
Signals were detected using chemiluminescence and quantified using the Syngene
GeneTools software.
2-deoxyglucose (2-DOG) uptake assay
Glucose uptake in 3T3-L1 was performed as described (Lakshmanan J 2003). Fully
differentiated 3T3-L1, untreated or after 24h of insulin resistance treatment (except in the
case of high insulin where the medium was changed to a low-glucose insulin-free
medium during the last hour to recover from chronic insulin treatment), was washed with
warm KRPH buffer and incubated in KRPH buffer at 37*C for 15 minute. For each
insulin resistant model or the control model, cells were divided into 2 groups: one for
determining basal glucose uptake (no insulin treatment) and the other for insulin-
stimulated glucose uptake (20nM insulin incubation for 30min). [3H]-2-deoxy-D-glucose
(PerkinElmer, 20pCi/ml) was added after the 30min insulin incubation, and glucose
uptake was measured by scintillation counting 10 min later. Data presented are mean
uptake ± SEM from 5 biological replicates. Counts per minute were converted to pmol of
2-deoxyglucose uptake per well.
RNA isolation and reverse transcription-PCR
Total RNA was extracted using Qiagen kit. lug of RNA was reverse-transcribed to
cDNA and used for quantitative PCR using SYBR Green I master mix in the Light
Cycler 480 instrument (Roche). At least three biological replicates were performed for
each experiment. Primers sequences are in Table 3-12.
RNA-Seq library preparation, sequencing and analysis
For each insulin resistance-inducing condition and the control condition, RNA-Seq
experiments on biological triplicates were performed. lOug of total RNA was used for
each RNA-Seq library preparation according to the manufacturer's instructions (Illumina).
Quality of RNA was verified using bioanalyzer (Agilent); only RNA with a RIN > 9 was
used for RNA-Seq. cDNA libraries were prepared and sequenced by Illumina GAII.
Pair-end, 36-bp reads from each sample were aligned to the mouse genome (mm9 build)
using TopHat (version 1.1.0). Differential expression of each insulin resistance model
versus the control model was quantified using Cuffdiff (Trapnell, Williams et al. 2010)
(version 1.0.3). Differentially expressed genes are those that have a log2 fold change of >
0.58 or < -0.58 and a q-value <0.05 when compared to the control condition. We also
required that the differentially expressed genes used for downstream analysis have a
FPKM greater than 0.1 in the control condition.
Microarray gene expression analyses
Expression data of DIO mouse fat pad (GSE14363, GSM498652 and GSE48220) and
adipogenesis (GSE80696, GSE14004 and GSE29899) were downloaded from GEO
database. GSE29899 is a RNA-Seq data set, and it was analyzed as described above.
Microarray expression data sets were analyzed using R and Bioconductor
(http://www.bioconductor.org/). Gene expression data were normalized and summarized
with the RMA algorithm (Irizarry, Hobbs et al. 2003) with an updated Entrez gene
probeset definitions (Dai, Wang et al. 2005). Differentially expressed genes were
identified using the LIMMA package (Smyth 2004). For the adipogenesis data sets, the
1,319 differentially expressed genes are those that have a log2 fold change of > 1 or < -1
and a q-value <0.05 between preadipocytes and adipocytes.
Gene set enrichment analysis (GSEA)
Gene set enrichment analysis was performed as described (Subramanian, Tamayo et al.
2005). For each insulin resistance model, rank-ordered gene list according to gene
expression fold changes with respect to the control model (untreated 3T3-L1 for the in
vitro models and normal chow diet-fed mouse for the DIO mouse models) was generated.
These ranked lists were used as input to GSEA, which mapped genes from members of
the publicly curated KEGG (Kanehisa and Goto 2000) and Reactome (Croft, O'Kelly et
al. 2010) pathways to the ranked-ordered lists. For each insulin resistance model and for
each pathway, a p-value was calculated to indicate the significance of upregulation or
downregulation of the particular pathway. The p-values were log transformed (-logio
pval) to an Enrichment Significance Score: upregulated pathways have positive
Enrichment Significance Scores (shown as red in heatmap), and downregulated pathways
have negative Enrichment Significance Score (shown in blue in heatmap), with the color
intensity representing the significance of upregulation/downregulation. White represents
no upregulation/downregulation, and grey represents uncalculated Enrichment
Significance Score as the number of mapped genes from a pathway to the rank-ordered
gene list is less than 10 (GSEA based on the 1,319-adipogenesis-related genes) or 15
(GSEA based on genome-wide data). Rows (pathways) in heatmap were ranked
according to the in vivo combined Enrichment Significance Scores, which were
calculated by summing the Enrichment Significance Scores of the 3 mouse models.
Hierarchical clustering
Clustering was done in Cluster (de Hoon, Imoto et al. 2004) and visualized in Treeview
(Saldanha 2004). For each insulin resistance model, the gene expression fold changes
(log2) with respect to the control model (untreated 3T3-L1 for the in vitro models and
normal chow diet-fed mouse for the DIO mouse models) were calculated, median
centered and normalized to have unit variance before clustering.
Principal component analysis
Gene expression fold change values with respect to the control model for each of the
seven insulin resistance models were normalized to have a mean of zero and unit variance
within each data set. Principal component analysis was then applied to the resulting
values. Projections of each model against the first two principal components were
computed and used to infer similarity between models.
Pathway visualization
Expression fold changes in the different pathways across the 4 in vitro models or the 7 in
vitro or in vivo models were visualized using PathVisio 2 (van lersel, Kelder et al. 2008).
Genes that are upregulated after the insulin resistant treatments (or in DIO mouse adipose
tissue) are shown as red, those that are downregulated are shown as blue. Missing
expression values are shown as green or grey.
DNase hypersensitivity cum sequencing (DHS-Seq) analysis
Intact nuclei were isolated from differentiated 3T3-L1 using a nuclei isolation kit (Sigma:
NUC201). Nuclei digestion and the DNA fraction isolation were done as described
(Sabo, Kuehn et al. 2006). In brief, at least 30 million nuclei were used for each
experiment. For each digestion, 50U/ml of DNase I (Promega RQ1 RNase-free DNase;
lot number: 25308616) was used for digesting 10M cells at 37*C. DNase I enzymatic
reaction was stopped after 2 min by a SDS- and EDTA-based stop buffer. Digested
nuclei were incubated at 55*C overnight with proteinase K. Digested DNA was then
extracted using phenol chloroform, and the "2-hit" DNA fragments were isolated using a
sucrose gradient. Isolated DNA fragments were purified, subjected to the standard
Illumina library preparation, and sequenced using Illumina GA II. 36-bp sequenced reads
were mapped to the reference genome mm9 using bowtie. Differential DNase
hypersensitive regions were identified using MACS (Zhang, Liu et al. 2008): TNFa-
induced DHS (+DHS) regions were called with the TNFa-treated cells as foreground and
the untreated control as background. Conversely, TNFa-repressed DHS (-DHS) regions
were called with the untreated control as foreground and the TNFa-treated cells as
background. Both +DHS and -DHS regions were called using a P-value threshold of 1E-
10.
DNA sequence motif discovery
Over-represented transcription factor motifs were identified in each experiment using
THEME (MacIsaac, Gordon et al. 2006). THEME uses principled statistical methods to
test hypotheses about the binding specificity of the immunoprecipitated protein.
Hypotheses are position weight matrix representations of DNA sequence motifs in the
TRANSFAC and JASPAR database. They were evaluated based on their cross-
validation error, which represents their ability to predict which sequences from a held-out
test set were bound by the protein and which were not. Each hypothesis was either
accepted or rejected based on a p-value, which was derived from comparing its predictive
value to those of motifs derived by applying the same algorithm to randomly selected
sequences for 25 times.
Chromatin Immunoprecipitation (ChIP) and ChIP-Seq
ChIP assays in 3T3-L1 were carried out as previously described (Lo, Bauchmann et al.
2011). Antibodies used for ChIP: p65 (abcam 7970) and C/EBPD (sc-150x). Primers
sequences used for ChIP-PCR analysis are in Table 3-12. ChIP-Seq was done essentially
as described (Lo, Bauchmann et al. 2011). ChIP-Seq libraries were prepared and
sequenced using the Illumina GAII protocol and platform. Single-end, 36-bp reads were
aligned to the mouse reference genome mm9. Peaks calling were done using MACS
(Zhang, Liu et al. 2008).
Mouse studies
Mice on the C57BL/6 background were kept at the University of Massachusetts Medical
School animal faculties. Mice were fed with a normal chow diet or a high-fat diet for 16
weeks starting from 8-week of age. All mice were sacrificed at 24 week. Glucose
tolerance test and insulin tolerance test were performed at week 23 to ensure that the
high-fat diet fed mice were insulin resistant.
3.7 Figures and Tables
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Figure 3-1 Setting up four in vitro insulin resistance models
(A) Western blot analysis of pAkt ser473 before and after 10m in of 2 0nM insulin
stimulation in 3T3-L for the control (untreated) model and the four insulin resistance
models. Bottom: Average fold change of Akt phosphorylation level before and after
insulin stimulation normalized to total Akt protein level (n3). An asterisk (*) indicates
p < 0.05 when compared with the control model by t-test. Error bars represent ± SEM.
(B) 2-deoxyglucose uptake in the basal state (open bars) and after 30mmn of 2OnM insulin
stimulation (solid bars) for the control (untreated) model and the four insulin resistance
models. Left: Average fold change of 2-deoxy-glucose uptake by dividing insulin-
mediated over basal uptake for each model (n=5). An asterisk (*) indicates p < 0.05
when compared with the control model by t-test. Error bars represent ± SEM.
(C) Expression of five adipocyte marker genes in the different models measured by
qPCR. Relative expression is calculated by normalizing with the house keeping gene
ribosomal protein S27 (Rps27). Data is presented as mean ± SEM (n=3). Statistical
significance is indicated (*p < 0.05, **p <0.01).
(D) Same as (C), but measured by RNA-Seq. Shown is the upper and lower bound
expression values calculated by Cuffdiff in FPKM. Statistical significance is indicated
(*q < 0.05).
(E) Pearson correlation coefficient between the gene expression fold changes (log 2) from
qPCR (C) and RNA-Seq (D).
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Figure 3-2 Illustration of gene expression changes across the four in vitro insulin
resistance models of the glycolysis and gluconeogenesis pathway
Each box represents a gene in the pathway; it is divided into 4 portions representing the
gene expression fold changes of the 4 in vitro insulin resistant models (with respect to the
control model). The expression fold changes are color-coded: upregulated genes are red
and downregulated genes are blue. The irreversible steps in the glycolysis and
gluconeogenesis pathways are indicated by blue and red arrows, respectively.
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Figure 3-3 Illustration of gene expression changes across the four in vitro insulin
resistance models of the triglyceride synthesis and degradation pathway
The same as 3-2.
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Figure 3-4 Anti-adipogenesis transcriptome shift of DIO mouse adipocytes captured
mainly by the TNFa and hypoxia models
(A) Heatmaps showing the 1,319 genes that are concordantly differentially expressed
between preadipocytes and differentiated adipocytes in three publications: AdipogenesisI
(Mikkelsen, Xu et al. 2010), Adipogenesis2 (Schupp, Cristancho et al. 2009), and
Adipogenesis3 (Sun et al, submitted). The 1,319 genes consist of 640 that are
upregulated (red) and 679 that are downregulated (blue) by greater than two-fold. Left:
hierarchical clustering of the expression fold changes during adipogenesis. Right:
hierarchical clustering of expression changes of the same genes in three independent
mouse models of diet-induced obesity (WATI, WAT2, and WAT3) and four 3T3-L1
insulin resistance models (TNFa, hypoxia, high insulin (High Ins), and dexamethasone
(Dex)). The expression fold changes were calculated as follows: for the mouse models:
adipose tissue from DIO vs. normal chow diet-fed mice; for the 3T3-Ll models: treated
3T3-Ll vs. untreated 3T3-Ll. For both clustering analyses, expression ratios were
converted to z-scores. Rows (genes) were pre-ranked according to the fold change of the
Adipogenesis3 data set, while columns were clustered using the Pearson correlation
similarity metric. The height of each arm of the dendrogram represents the distance
between the different data sets.
(B) The percentage of the concordantly differentially expressed genes from panel A that
are altered in each data set. Red bars represent the percentage of upregulated genes and
blue bars represent the percentage of downregulated genes. Top panel showing the
expression changes of the 640 adipogenesis-induced genes, among which 352 are
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downregulated in at least one of the mouse data sets; bottom panel showing the 679
adipogenesis-repressed genes, among which 298 genes are upregulated in at least one of
the mouse data sets. Upregulation or downregulation was defined as having a log2 fold
change of > 0.58 or < -0.58 when compared to the control data set. P-values (indicating
whether the percentage is significantly larger than expected) were calculated using 1-
sample proportion test (p < 1E-5: *; p < lE-10: **).
(C) Venn diagrams showing the overlap of genes that are differentially expressed in each
in vitro model. Top: The number of genes that are repressed in each of the in vitro
models among the 352-adipogenesis-induced-DIO-repressed genes. Bottom: The
number of genes that are induced in each of the in vitro models among the 298-
adipogenesis-repressed-DIO-induced genes. The letters next to the numbers of genes are
used to indicate the particular category in Tables 4 and 5.
(D) Principal components analysis (PCA) of the seven models. Each principal
component (PC 1 and PC2) represents a direction of maximal variation in the matrix of
expression data. The models are projected onto the first two principal components, with
the cell line models shown as yellow dots and the mouse models shown as green dots.
The distance between dots on each line corresponds to the distance between models along
this projection. The numbers in parentheses represent the fraction of the variance in the
expression fold change matrix that is explained by that particular principal component.
Left: PCA using the 1,319 adipogenesis-related genes. Right: PCA using 13,043 genes
with FPKM > 0.1.
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Figure 3-5 Results of hierarchical clustering of the 1,319 adipogenesis-related genes
using other similarity metrics
Hierarchical clustering results of the 1,319 adipogenesis-related genes among the seven
insulin resistance models using two other similarity metrics. In the heatmap obtained
using Euclidean distance, the TNFa model clusters with the DIO mouse models; in the
heatmap obtained using Spearman correlation, both the TNFa and hypoxia models cluster
with the mouse models.
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Thirteen of the 15 top upregulated pathways are related to the cell cycle process and
DNA replication.
(D) Heatmap showing the results from gene set enrichment analysis (GSEA) of genome-
wide transcription data. The analysis is the same as in panel A, except that gene set
enrichment analysis was done using all genes, and the KEGG and Reactome pathways
were required to have more than 15 genes mapped to the ranked expression data set; 479
pathways were used as a result.
(E) Illustration of the top 15 pathways downregulated in vivo (ranked as in panel D),
which is based on genome-wide GSEA. The majority of the downregulated pathways are
related to metabolism.
(F) Illustration of the top 15 pathways upregulated in vivo (ranked as in panel D), which
is based on genome-wide GSEA.
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Figure 3-7 Illustration of gene expression changes across the seven models of the
valine, leucine and isoleucine degradation pathway
Each box represents a gene in the pathway; it is divided into 7 portions representing the
gene expression fold changes of the 7 models (with respect to its control). The
expression fold changes of each model are color-coded: upregulated genes are red and
downregulated genes are blue, grey and green represents unavailable data. The genes in
the pathway are arranged according to the enzymatic reactions that they are involved in
as presented in the KEGG illustration.
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Figure 3-8 Illustration of gene expression changes across the seven models of the
insulin signaling pathway
The same as 3-7.
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Figure 3-9 Illustration of gene expression changes across the seven models of the
triglyceride synthesis and degradation pathway
The same as 3-7.
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Figure 3-10 Illustration of gene expression changes across the seven models of the
tricarboxylic acid cycle
The same as 3-7.
Figure 3-11 Illustration of gene expression changes across the seven models of the
electron transport chain
The same as 3-7.
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Figure 3-12 Illustration of gene expression changes across the seven models of the
glycolysis and gluconeogenesis pathway
The same as 3-7.
AAA
4 dMUE V Sk'~
Liiw%% I- -I
IM"W
O OS AL-A
-TWO
G~wNice
EN4
.rNrl Sep t-0
-Twoa
-Two
"0- ALV
-TN~a TNFa
pO.A9pi13-
iji-~
Fl1
IC IC ~ T TIK .
Figure 3-13 Identifying keys regulators of TNFa-induced insulin resistance
(A) UCSC genome browser tracks showing the Pparg locus. Left: An asterisk (*)
indicates DNase hypersensitive regions identified by the current study overlap with those
in Day 6 differentiated 3T3-Ll (Siersbaek, Nielsen et al. 2011) and mouse fat pad
(Birney, Stamatoyannopoulos et al. 2007), as well as PPARy bound sites identified from
PPARy ChIP-Seq in 3T3-L1 (Mikkelsen, Xu et al. 2010). Arrows indicate the direction
of transcription. Y-axis represents the height of the mapped sequenced reads and is the
same for all tracks.
(B) UCSC genome browser tracks showing representative examples of genomic regions
with altered DNase hypersensitivity after TNFa treatment. Gain in DNase
hypersensitivity: Lcn2 (top left) and Serpinel (bottom left); loss in DNase
hypersensitivity: Cfd (top right) and ScdJ (bottom right). Genomic regions with a gain or
loss of DNase hypersensitivity are underlined in red. +TNFa represents DHS-Seq after
24h of TNFa treatment; -TNFa represent DHS-Seq from unstimulated cells. Arrows
indicate the direction of transcription.
(C) Genes within 10kb of regions with altered DNase hypersensitivity are more likely to
be differentially expressed. An increase in DNase hypersensitivity is associated with an
increase in expression and vice versa.
(D) Changes of DNase hypersensitivity near PPARy and p65 binding sites. Plots show
the average number of tag counts from DHS-Seq experiments in a 2kb window around
experimentally determined binding sites for PPARy (left), E2F4 (middle) and p65 (right).
P-values were calculated based on the tag counts from the DNase hypersensitivity
experiments using Wilcoxon rank sum tests.
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(E) The top two DNA sequence motifs from the p65 ChIP-Seq experiment as determined
by THEME. Cv error represents cross-validation errors. P-values were calculated as
described in Methods.
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Figure 3-14 Selected locus with differential DNase hypersensitivity after the
different insulin resistant treatments
UCSC genome browser tracks showing the thrombomodulin (Thbd) locus with altered
DNase hypersensitivity after the different insulin resistance treatments. The differential
hypersensitive region (in a red box) occurs at -5700 bp after the Thbd transcription start
site. Arrow indicates the direction of transcription.
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Figure 3-15 Relationship between changes in gene expression and DNase
hypersensitivity of genes located within 2kb of regions with altered DNase
hypersensitivity
Same as Figure 3-13C, except that genes analyzed are within 2kb of regions with altered
DNase hypersensitivity. Of the 59 genes that are located within 2kb of regions with
decreased DNase hypersensitivity 32% of the genes (19 genes) are downregulated (p <
2.2E-16) and none is upregulated (p =1). Conversely, of the 318 genes located within
2kb of regions with increased DNase hypersensitivity 53% of the genes (168 genes) (p <
2.2E-16) are upregulated and only 2.8% (9 genes) are downregulated (p=l). Several
genes with concordant gene expression and DNase hypersensitivity changes are indicated
in the figure: increase in gene expression and DNase hypersensitivity (chemokine (C-C
motif) ligand 5 (CcI5), lipocalin 2 (Lcn2), and inhibitor of kappa light polypeptide gene
enhancer in B-cells kinase epsilon (Ikbke)); decrease in gene expression and DNase
hypersensitivity (Adipsin (Cfd), Hormone-sensitive lipase (Lipe), and glycerol-3-
phosphate dehydrogenase 1(GpdI)).
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Figure 3-16 The role of C/EBPP in TNFa-induced insulin resistance
(A) mRNA expression values in FPKM of the 6 C/EBP isoforms from untreated (-TNFa,
control) and treated (+TNFa) 3T3-L1 measured by RNA-Seq. FC: log 2 fold change of
expression values (+TNFa/ -TNFa), qval is determined by Cuffdiff.
(B) Western blot analysis of C/EBP$ protein expression from untreated (-TNFa, control)
and treated (+TNFa) 3T3-L1. Bottom panel: Quantification of protein expression level
normalized to total Akt loading control, scale bars are mean ± SEM (n=4). An asterisk
(*) indicates p < 0.05 by t-test.
(C) mRNA expression levels of Cebpb on white adipose tissue from mice on a high-fat
diet (HFD) and a normal chow diet (ND) measured by qPCR (n=5). Relative expression
is normalized to Rps27.
(D) Western blot analysis of C/EBPD protein expression from white adipose tissues from
HFD mice and ND mice (n=5). Bottom panel: Quantification of protein expression level
normalized to total Akt loading control, scale bars are mean ± SEM (n=5). An asterisk
(*) indicates p < 0.05 by t-test.
(E) ChIP-PCR analysis of control (open bars) and TNFa-treated (close bars) 3T3-L1
showing C/EBPD occupancy on selected loci. C/EBP$ binding to negative control region
Gene -TNFa +TNFa FC qval
Cebp 46.3 9.1 -2.3 0
Cebp 35.7 75.4 1.1 2E-11
Ceb 8.9 24.4 1.5 9E-12.
Ceb 0 0 NA NA
Ceb 30.5 19.9 -0.6 4E-5
Ddit3 173.4 222.8 0.3 7E-3
10.5
e 10.0
9.5
9.0
8.5
8.0
7.5
C/EBP3 mRNA
(Alb) is shown for comparison. % of input on selected loci from ChIP experiment with
C/EBP$ antibody or non-specific IgG is indicated. Error bars indicate mean ± SEM
(n=3). An asterisk (*) indicates p < 0.05 by t-test.
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Figure 3-17 Gene expression changes of selected marker genes after 24h and 48h of
TNFa treatment
Expression of TNFa-responsive genes in unstimulated cells (-TNFa) and after 24h and
48h of TNFa treatment (+TNFa) measured by qPCR. Relative expression is calculated
by normalizing with the house keeping gene ribosomal protein S27 (Rps27). Data is
presented as mean ± SEM (n=4). NS: not significant by t-test.
Table 3-1 Number of the upregulated genes of each in vitro model and their
enriched gene ontology categories
TNFa 1307 immune response 111 9.80E-29
defense response 75 6.40E-10
Dex 547 response to peptide hormone stimulus 16 1.80E-04
positive regulation of programmed cell death 24 1.00E-03
High
Ins 719 sterol biosynthetic process 19 1.20E-15
lipid biosynthetic process 46 5.60E-14
Hypoxia 786 transcription 143 4.50E-14
glycolysis 16 5.30E-08
Only the top two categories were shown. *P-values were calculated by Fisher-Exact tests
assessing the significance of over-representation. Multiple hypothesis testings were
corrected by Benjamini-Hochberg correction.
Table 3-2 Number of the downregulated genes of each in vitro model and their
enriched gene ontology categories
TNFa 1388 fatty acid metabolic process 39 1.50E-06
negative regulation of biosynthetic
process 64 1.10E-05
Dex 486 NA
High Ins 924 translation 40 3.60E-05
_ transcription 122 1.80E-03
Hypoxia 1158 oxidation reduction 81 8.40E-08
fatty acid metabolic process 36 1.10E-07
Only the top two categories were shown. *P-values were calculated by Fisher-Exact tests
assessing the significance of over-representation. Multiple hypothesis testings were
corrected by Benjamini-Hochberg correction.
Table 3-3 Diet-induced obese mouse expression data sets used in this study
WATI 60% 12 weeks
WAT2 30% 24 weeks
WAT3 45% 13 weeks
* indicate the percent of calories from fat
Microarray GSE14363
Microarray GSM498652
Microarray GSE28440
Table 3-4 Adipogenesis data sets used in this study
3T3-L1 preadipocyte
differentiation in vitro Adipogenesis1 Microarray GSE20696
3T3-L1 preadipocyte
differentiation in vitro Adipogenesis2 Microarray GSE14004
Primary preadipocyte
differentiated in vitro Adipogenesis3 RNA-seq GSE29899
Table 3-5 Expression changes of the 352 adipogenesis-induced-DIO-repressed genes
in the different in vitro models
a+b+d+e 214 TNFa fat cell differentiation 10 8.4E-06
b+c+e+f 134 Hypoxia oxidation reduction 18 2.OE-04
d+e+f+g 62 Dex lipid catabolism 6 2.OE-02
a 104 Only TNFa fat cell differentiation 7 3.9E-04
b+e 63 TNFa + hypoxia oxidation reduction 11 4.OE-03
None among TNFa,
h 93 hypoxia or Dex oxidation reduction 23 1.4E-10
The different categories are indicated in Figure 3-4C. *P-values were calculated by
Fisher-Exact tests assessing the significance of over-representation. Only the top GO for
each category is shown. Multiple hypothesis testings were corrected by Benjamini-
Hochberg correction.
Table 3-6 Expression changes of the 298 adipogenesis-repressed-DIO-induced genes
in the different in vitro models
a+b+d+e 106 TNFa
immune system
process 5.6E-05
b+c+e+f 57 Hypoxia M phase 11 2.7E-05
d+e+f+g 96 High Ins M phase 30 2.6E-31
immune system
a 70 Only TNFa process 15 1.8E-03
g 64 Only high ins cell division 26 4.1E-27
None among TNFa,
h 98 hypoxia or high ins DNA replication 12 1.6E-06
The different categories are indicated in Figure 3-4C. *P-values were calculated by
Fisher-Exact tests assessing the significance of over-representation. Only the top GO for
each category is shown. Multiple hypothesis testings were corrected by Benjamini-
Hochberg correction.
Table 3-7 DNA sequence motif analysis of regions that gain DNase hypersensitivity
after the different insulin resistance treatments
Bach,FRA1 6.6E-135 0.28
CREB 3.4E-109 0.37
NF-kappaB 2.6E-102 0.33
C/EBP 3.OE-102 0.37
Tax/CREB 3.OE-93 0.40
Nrf-2 8.2E-86 0.33
RORA 7.8E-67 0.41
TEF-1 1.8E-55 0.41
1k-1 4.7E-46 0.40
DEAF1 2.1E-31 0.42
Bach 3.9E-210 0.28
Nrf-2 4.7E-111 0.33
Tax/CREB 4.1E-84 0.36
RORA 8.6E-70 0.38
CREB 1.5E-59 0.37
PPARG 2.5E-42 0.45
MyC 4.9E-38 0.42
ArntfHif 1.7E-33 0.42
ER 5.3E-24 0.41
Pax 7.OE-24 0.43
Arnt/Hif 7.46E-109 0.39
Bach 8.16E-104 0.37
Nrf-2 8.56E-54 0.41
Myc 9.06E-40 0.38
VDR:RXR 4.35E-37 0.41
C/EBP 1.23E-32 0.40
CREB 1.72E-28 0.43
TEF 4.44E-28 0.40
NF-1 1.66E-24 0.45
E2F 5.7E-24 0.44
NF-1 4.5E-22 0.42
AP-
2alpha 3.1E-14 0.46
Zfx 1.8E-12 0.46
Whn,
AhR 2.2E-10 0.45
Arnt/Hif 2.9E-10 0.45
MIZF 1.4E-08 0.44
CNOT3 4.8E-08 0.46
PEA3 4.9E-08 0.47
Olf-1 2.OE-07 0.46
Motifs highlighted in bold are those with a cross-validation error (CV error) <0.4.
GR 9.81E-186 0.33
Table 3-8 DNA sequence motif analysis of regions that lose DNase hypersensitivity
after the different insulin resistance treatments
MyoD,TCF3 2.3E-95 0.40
NF-1 3.6E-90 0.39
Arnt/Hif 1.9E-69 0.43
E2F 2.4E-52 0.40
Myc 5.7E-41 0.43
Tal-1 5.7E-31 0.39
TGIF 3.6E-27 0.44
AP-4 2.1E-26 0.45
XBP-1 6.4E-25 0.44
PPAR 1.1E-22 0.44
Hypoxia
XBP1 1.9E-29 0.43
Mye 8.7E-28 0.41
NRF1 6.1E-20 0.42
MyoD,TCF3 5.7E-15 0.42
AP-4 6.OE-14 0.43
AhR, Amt,
HIF-1 7.9E-11 0.43
TCF3 1.1E-08 0.44
TTF1 1.OE-07 0.44
MTF1 4.8E-06 0.45
P53 1.3E-05 0.46
nevxnqmethasone
NF-1 1.2E-75 0.42
MyoD,TCF3 2.9E-46 0.41
HENI 2.7E-24 0.43
Elk-1 1.OE-20 0.45
Tal-1 3.6E-20 0.42
Nanog 2.8E-19 0.45
AP-4 5.6E-18 0.44
AP-2alphaA 4.2E-17 0.46
E2F 1.8E-16 0.43
Lkzfl 3.1E-15 0.45
Hig Insulin
Nrf-2 4.2E-79 03
E2F7 6.1E-65 0.42
Myc 3.7E-48 0.40
Arnt/Hif 1.9E-45 0.38
RORA 1.2E-44 0.40
Bach 3.8E-43 0.34
Tax/CREB 3.4E-40 0.41
XBP-1 8.2E-35 0.40
C/EBP 1.1E-33 0.41
ATF6 1.6E-32 0.42
Motifs highlighted in bold are those with a cross-validation error (CV error) <0.4.
Table 3-9 DNA sequence motif analysis of regions that lose DNase hypersensitivity
locating within 10kb of the TNFa-repressed genes
PPAR 7.24E-15 0.43
Myc 7.58E-15 0.44
Hmx3 8.91E-14 0.46
NF-1 1.64E-13 0.44
Arnt 1.41E-12 0.46
Nanog 2.34E-09 0.45
FOXD3 1.18E-08 0.47
E2F 1.90E-08 0.46
HNF4 4.51E-08 0.45
Table 3-10 DNA sequence motif analysis of regions that gain DNase hypersensitivity
locating within 10kb of the TNFa-induced gene
AP-1 2.13E-94 0.40
NF-kappaB 1.91E-36 0.37
ETS 9.28E-36 0.41
TEF 6.34E-25 0.44
RORA 8.45E-21 0.43
GABP 6.23E-15 0.43
CREB 1.26E-13 0.46
IRF 1.29E- 11 0.43
Elk 2.95E-09 0.44
Nkx 5.53E-09 0.45
STAT 6.80E-09 0.45
C/EBP 2.3 1E-08 0.45
Motifs highlighted in bold are those with a cross-validation error (CV error) <0.4.
Table 3-11 DNA sequence motif analysis of enriched regions identified from p65
ChIP-Seq experiment
NF-kappaB 2.94E-164 0.27
C/EBP 8.06E-53 0.37
PARP 8.26E-43 0.43
TEF-1 3.50E-27 0.43
RBP-Jkappa 2.42E-19 0.44
GABP 2.92E-19 0.42
E2F 1.34E-18 0.41
Olf-1 1.79E-18 0.43
Helios A 8.32E-16 0.42
MAF 5.53E-15 0.45
HSF 7.14E-14 0.45
MIZF 2.09E-13 0.42
STAT 1.82E-11 0.44
EBF 2.24E-10 0.43
Motifs highlighted in bold are those with a cross-validation error (CV error) <0.4.
Table 3-12 Primers used in the current study
qPCR pimers
Adipoq TGGAATGACAGGAGCTGAAGG
GCGAATGGGTACATTGGGAAC
Fasn GGAGGTGGTGATAGCCGGTAT
TGGGTAATCCATAGAGCCCAG
Pparg TCGCTGATGCACTGCCTATG
GAGAGGTCCACAGAGCTGATT
Glut4 GTGACTGGAACACTGGTCCTA
CCAGCCACG'TGCATTGTAG
Glut1 CAGTTCGGCTATAACACTGGTG
GCCCCCGACAGAGAAGATG
Cebpa CCCACTCAGCTTACAACAGG
GCTGGCGACATACAGTACAC
Cebpb ACACGTGTAACTGTCAGCCG
GCTCGAAACGGAAAAGGTTC
Rps27 CCTTCATCCCTCTCCAGAAGA
CCGTGGTGATTTTATAGCATCTC
ChIP-PCR primers
Lcn2 GCGGGGTAGTCCATCCTTTACCA
CCCTGTGCCTGCCAGAATCCAA
Socs3 AGAAACATAAAACTCCCGTCT
CCCCATAAGCACAGATCAGC
Irf2 TCTGCCCACCTCTTACCAC
CCAATGCCCCATGAGTCG
Gluti ACAGCCCGTCATTGCAAG
CCTACTGTGCCCGTCCA
1115 ATCGCCTCAAAGCTTGGTC
CGGCCAATAACATTGAGTCAC
Alb CAATGAAATGCGAGGTAAGTATGG
TCTTTAACCAATAACTGTAGATCATTA
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Conclusion
In this thesis, through a series of complementary experimental and computational
analyses, we have presented a genome-wide perspective on transcriptional regulation of
adipocyte and adipose insulin resistance. Our studies provided a wealth of new resources
for future studies. The work in this thesis is divided into 2 major sections.
In Chapter 2, we characterized the genome-wide location of a largely unknown
histone modification, H3K56 acetylation. Our results uncover the extensive genomic
converge of this histone modification. We further show that many genes involved in the
adipokine signaling and type 2 diabetes pathways have a previously-unknown high level
of H3K56 acetylation, giving rise to the possibility that this modification is important for
normal adipocyte function and proper transcriptional regulation. It will be interesting to
study whether there is any alteration of this particular histone modification in insulin
resistance.
In Chapter 3, we established and characterized four different in vitro models of
insulin resistance in the mouse cell line 3T3-L1. By comparing their transcriptome
changes with those of adipose tissue from DIO mice, we show that the TNFa and
hypoxia models are most able to capture the downregulation of the various glucose, lipid
and amino acid metabolic pathways. Furthermore, it is the TNFa model that captures the
upregulation of the inflammatory and chemotactic responses, and the high insulin and to
a lesser extent, the hypoxia model that capture the upregulation of cell cycle-related
processes upon adipose insulin resistance. The dexamethasone model bears little
similarity with the DIO mouse adipose tissue at the transcriptome level.
Our study shows that while no in vitro model among the four that we studied
mimics the full range of transcriptome changes occurring in DIO adipose tissue, different
in vitro models capture different aspect of in vivo adipose insulin resistance.
Furthermore, it provides interesting insights into the problem of insulin resistance in a
number of ways. Firstly, although chronic, low-grade inflammation is a key feature of
obesity-induced insulin resistance, insulin resistance can occur without inflammation at
least in the cell culture settings, where we show that dexamethasone-, high insulin-, and
hypoxia-induced insulin resistance all occur without marked inflammation. This has
implications for current clinical trials using anti-inflammatory strategies to treat insulin
resistance (e.g., the high-dose aspirin regimen and the TNFa neutralizing strategy). Take
the TNFa antibody neutralizing strategy as an example: in a recent clinical trial in which
the TNFa antibody etanercept was administered to patients with metabolic syndrome, it
was found that although the etanercept-treated group showed favorable improvements in
inflammatory markers, including a significant decrease in C-reactive protein and an
increase in total adiponectin, insulin sensitivity did not differ from participants that
received placebo (Bernstein, Berry et al. 2006). This disappointing result, together with a
similar failure a decade ago (Ofei, Hurel et al. 1996), suggests that neutralizing the
inflammatory responses caused by TNFa is not sufficient to restore insulin sensitivity.
Secondly, we identified at least two features of adipose insulin resistance that are
common among the three DIO adipose insulin resistance models and are captured by the
TNFa and hypoxia models, but they are not the typical, well-studied signatures of DIO
insulin resistance: 1) the downregulation of genes related to the P450 detoxification
system. 2) The downregulation of genes responsible for the degradation of branched-
chain amino acids. These features were identified through comparison among the three
different DIO mouse models, which has never been performed prior to our present study.
This highlights the abundance of information that the literature offers and the exciting
challenge of how to extract these and other often diverse sets of information for novel
biological insights. The next chapter describes our vision of integrating different
experimental results to extend our understanding of insulin resistance.
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4. Future Perspectives
4.1 Overview
The goal of this section is to discuss other methods that would lead to a more
comprehensive, systemic view of adipose insulin resistance. The literature is not lacking
in articles documenting that knocking out or expressing a dominant-negative version of a
particular gene protects mice from DIO-induced insulin resistance. A few selected
examples are summarized in Table 5-1. Undoubtedly, these studies have shed light into
the various molecular mechanisms and potential therapeutic targets of insulin resistance;
however, the cellular state changes in knock-out mice are often too se vere to be
physiologically relevant-it is impractical to totally knock-out a particular gene in
humans. Indeed, except for the few rare cases where particular genetic mutations lead to
insulin resistance, the cause of most common forms of human insulin resistance is multi-
factorial and multigenic; it is likely to be the consequence of multiple defects on both the
transcriptional and signaling levels. The pressing problems and challenges are how to
identify those defective components, some of which are often "hidden" from
experimental hits, and how to connect the different components in order to identify the
Achilles heel(s) for effective therapeutic interventions. Lastly, on a more biological front,
we discuss the idea that we could potentially regard adipose insulin resistance as a
differentiation defect as well as a dedifferentiation abnormality.
Table 4-1 Knock-out mouse models that show favorable outcomes upon high-fat diet
challenges
Inhibitor kappaB kinase epsilon Kinase
(Chiang, Bazuine
et al. 2009)
(Wu, Roth et al.
Dusp1 MAP kinase phosphatase-1 Phosphatase 2006)
(Ma, Mao et al.
Serpinel Plasminogen activator inhibitor Adipokine 2004)
cAMP responsive element binding Transcription (Qi, Saberi et al.
CrebI protein 1 factor 2009)
(Minamino,
Transcription Orimo et al.
Tp53 p53 tumor suppressor factor 2009)
Forkhead box-containing protein 0 Transcription (Nakae, Cao et al.
Fox01 subfamily factor 2008)
Transcription (Jiang, Qu et al.
Hifla Hypoxia inducible factor 1 alpha factor 2011)
Aryl hydrocarbon receptor nuclear Transcription (Jiang, Qu et al.
Arnt translocator factor 2011)
Ikbke
Some of the above models use a dominant-negative version of the particular gene rather
than knock-out the gene
4.2 Transcription factor network
The work in this thesis mainly focuses on characterizing one single histone modification
(H3K56 acetylation in Chapter 2) and a few transcription factors (p65 and C/EBPp in
Chapter 3). In both chapters, through DNA sequence motif analysis, we identified
additional transcription factors that may be involved in normal adipocyte function and
adipose insulin resistance. Transcription, even for a single gene, is a highly regulated
process involving multiple trans-acting factors and cis-acting elements. Take the IFN$
gene as an example, one of its enhancer regions is simultaneously bound by the p50 and
p65 subunits of NF-kB, ATF-2, IRF-3, IRF-7, c-Jun, and HMGA. Identifying genome-
wide binding sites for multiple transcription factors enable the construction of
transcriptional network motifs, which are the building blocks that make up transcriptional
regulatory network (Lee, Rinaldi et al. 2002). This is important because a network
perspective allows us to understand the components, the interactions and the connectivity
of a system, which is crucial when it comes to understanding human diseases and
designing new strategies to combat diseases.
While genome-wide transcription factor profiling has been carried out
comprehensively in yeast (ChIP-chip were performed on 106 epitope-tagged transcription
factors) (Lee, Rinaldi et al. 2002), such approach seems formidable for mammalian
systems: tagged-versions of transcription factors are harder to generate and may interfere
with the normal physiological processes, and the number of transcription factors in
human and mouse is more than one magnitude greater than that in yeast. Despite these
challenges, genome-wide location analyses on multiple transcriptional factors have been
performed in various mammalian systems, most notably in the liver (Odom, Zizlsperger
et al. 2004; Odom, Dowell et al. 2006) and embryonic stem cells (Boyer, Lee et al. 2005;
Chen, Xu et al. 2008; Kim, Chu et al. 2008). However, the above studies require
knowledge of which transcription factor to profile a priori. Approaches like DNase
hypersensitivity experiment followed by sequence motif analysis enable us to identify
previously unknown transcription factor targets and prioritize these targets for
experiments.
In the case of TNFa-induced insulin resistance, the AP-1 and NF-xB motifs are
the top motifs enriched in the DNase hypersensitivity regions induced by TNFa. Both
transcription factors have long been implicated in insulin resistance. Other potential
regulators identified by motif analysis include thyrotrophic embryonic factor (TEF), ETS
transcription factor, RAR-related orphan receptor A (RORA) and GA binding protein
transcription factor (GABP), etc. There is no doubt that some of these may represent
false positives from motif analysis. By combining DNase hypersensitivity analysis with
other sources of evidence (histone modification, gene expression and ChIP-Seq data, etc),
we would be better able to identify bona fide novel regulators involved in insulin
resistance.
4.3 Extending beyond transcription
While the focus of this thesis has been on transcriptional regulation and transcriptional
outcomes, proteins, instead of genes, are the actual executors of cellular functions.
Although transcription is the obligatory step for translation to occur, changes in mRNA
expression often do not translate to changes in protein expression (Tian, Stepaniants et al.
2004). Moreover, many signaling cascades are mediated by changes in post-translational
modifications (e.g., phosphorylation, acetylation, ubiquitination and SUMOylation)
rather than the expression level of proteins: the insulin signaling pathway, which is
essentially a phosphorylation-mediated pathway, is a classic example. Phosphorylation
of many key nodes in the insulin signaling pathway (insulin receptor, insulin receptor
substrate and Akt, etc) is compromised during insulin resistance. In addition,
inappropriate or excessive activation of kinases, such as IKK and JNK, also lead to
insulin resistance. Thus, dysregulation of protein phosphorylation is a key feature of
insulin resistance. In order to obtain a comprehensive understanding of insulin resistance,
we need to interrogate other aspects of cellular functions besides transcription.
One such approach is phosphoproteomics by mass spectrometry (MS), which has
the ability to discover novel protein phosphorylation sites and provide a quantitative
characterization of the phosphorylation levels in the whole proteome in an unbiased
manner. For example, the tyrosine phosphorylation response upon 150nM of insulin
stimulation after 0, 5, 15 and 45 min was measured by MS (Schmelzle, Kane et al. 2006).
This results in the identification and relative temporal quantification of 122 tyrosine
phosphorylation sites on 89 proteins, of which only 20 were known to be associated with
insulin stimulation. It will be interesting to apply the same approach to insulin resistant
3T3-L1 and mouse adipose tissue to identify alterations in tyrosine phosphorylation in the
diseased state.
The experimental approaches that we took in this thesis and those proposed above
often result in the identification of an unprecedentedly large number of hits for
downstream analysis. The question then becomes how to identify the most relevant hits
to follow up. In addition, hits identified through different methodologies are often
distinct. While hits supported by multiple sources of evidence are likely to be the critical
nodes in the system under study, many of these obvious hits (low-lying fruits) have
already been identified. Furthermore, some important components of a particular system
may not even be identifiable by different techniques due to the systematic bias and
limitation of the techniques. To overcome the above problems, various computational
approaches have been proposed to integrate different sources of data (Huang and
Fraenkel 2009; Yeger-Lotem, Riva et al. 2009; Cheng, Yan et al. 2011). For example,
Huang et al has recently applied a constrained optimization approach, based on the prize-
collecting Steiner Tree algorithm, to connect transcriptional data with proteomic data via
protein-protein and protein-DNA interactions (Huang and Fraenkel 2009). We envision
that such approach will facilitate the identification of both novel and well-established
nodes important in insulin resistance.
4.4 Adipocyte insulin resistance, differentiation,
and dedifferentiation
Adipose insulin resistance could be perceived as a failure to generate sufficient functional
mature adipocytes to execute the normal physiological functions of adipocytes (lipid
storage, glucose uptake, and adipokine secretion). It is proposed that failure of adipocyte
differentiation could cause type 2 diabetes (Danforth 2000). This is supported by the
observation that transplanting functional adipocytes into lipoatrphic diabetic mice
improves their insulin sensitivity (Gavrilova, Marcus-Samuels et al. 2000). Furthermore,
the antidiabetic agent TZD mediates its insulin-sensitizing action by enhancing adipocyte
differentiation. In addition, insulin resistance as a result of the side-effects of
antiretroviral therapy HIV-1-protease inhibitors is associated with adipocyte
differentiation defects. Fats from HIV-1-protease inhibitors users who developed
peripheral lipoatrophy were shown to contain a higher proportion of small adipocytes that
have reduced expression of adipogenic transcription factors; these cells presumably have
reduced differentiation potential (Bastard, Caron et al. 2002). The above evidence
suggests that adipose insulin resistance could be seen as a differentiation defect.
Conversely, adipose insulin resistance also represents a defect of mature adipocytes to
carry out their normal functions. Take TNFc-induced insulin resistance as an example, it
is characterized by induction of preadipocyte genes and repression of adipocyte-specific
genes-a state of dedifferentiation (Engelman, Berg et al. 2000; Ruan, Hacohen et al.
2002). Our results confirm these previous findings and show that this is also the case in
DIO mouse adipose insulin resistance (Figure 3-4 and Tables 3-5 and 3-6). Since there is
a marked elevation of TNFa in obesity and insulin resistance, it is plausible that in vivo
adipose insulin resistance could be associated with a certain degree of adipocyte
dedifferentiation.
It will be interesting to delineate how the defect in adipocyte differentiation and
the aberration of dedifferentiation contribute to adipocyte insulin resistance. The
adipocyte differentiation process, also known as adipogenesis, is extensively
studied(Camp, Ren et al. 2002; Tang, Otto et al. 2003; Mikkelsen, Xu et al. 2010). It is a
multi-step process involving the interplay of multiple transcription factors; defect in any
of these transcription factors could block or impair differentiation. Mounting evidence
shows that PPARy, or more specifically, the lack of PPARy, is one of the contributing
factors. Conversely, the process of dedifferentiation is less understood. While
dedifferentiation is unlikely to follow the exact reverse path of differentiation, it is
plausible that it utilizes some common transcription factors with the differentiation
process.
Our study identified that C/EBPp is elevated upon TNFa-induced insulin
resistance, and C/EBPP also binds to the cis-regulatory regions of various TNFa-induced
genes. Recent study identified C/EBP$ as a pioneering factor for adipogenesis
(Siersbaek, Nielsen et al. 2011). It is suggested that C/EBP$ plays a key role in initiating
the early chromatin remodeling steps necessary for the subsequent binding of late-acting
transcription factors (eg PPARy). C/EBPp expression increases during early
adipogenesis and declines as differentiation proceeds. It will be interesting to investigate
whether ectopic expression of C/EBPp in the late differentiation stage would impair
differentiation, and whether ectopic expression of C/EBPP in mature adipocytes would
lead to dedifferentiation.
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